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By the time he reached eighteen
eighteen months
months of age,
age, Stefan
Stefan Ferrari
Ferrari had
By
required childhood
childhood vaccines.'
vaccines. I His parents
parents recall
recall
received many of his required
received
difficulty
that he was a healthy child who displayed no difficulty
communicating verbally?
Following his last set of booster shots,
verbally.2 Following
communicating
years old, Stefan still has
Stefan stopped talking. 33 Now ten years
however, Stefan
44
spoken.
not
Stefan's parents filed suit against the manufacturers
manufacturers of the various
neurological damage5
vaccines he received,
received, alleging their son suffered neurological
vaccines
preservative
mercury-containing
a
from thimerosal, mercury-containing preservative in
in the
the vaccines.
vaccines. 5
Stefan's parents
parents claim
claim that the vaccines
vaccines could
could have
have been made with a
safer, mercury-free
preservative, or they could have been
mercury-free preservative,
manufactured
single-dose vials, which do not require a
manufactured in single-dose
State University
University College
2010, Georgia
J.D. Candidate,
Candidate, 2010,
* J.D.
Georgia State
College of
of Law.
Law.
FederalLaw a Roadblock: Lawyer for
Suit, Parents
ParentsAsk
I.
Allow Vaccine Suit,
Ask Justices;
Justices; Federal
1. Bill Rankin, Allow
Court, ATLANTA J.Deserves Day in Court,
Nine Years Deserves
Couple
Hasn't Spoken for
for Almost Nine
Who Hasn't
Couple Says Boy Who
available at 2008 WLNR 9552686.
2008, at BI, available
CONST., May
CONST.,
May 21,
21,2008,
2. Id.
ld.
3. ld.
Id.
Id.
4. Id.
aft'd, 668 S.E.2d
5. Ferrari v. Am.
Am. Home Prods. Corp., 650 S.E.2d 585, 586 (Ga. Ct. App. 2007), ajJ'd,
236, 243 (Ga. 2008). For a discussion of the use of thimerosal in vaccines and its potential link to severe
236,243
(Thimerosal),
Control and Prevention, Mercury
side effects, see
Mercury and Vaccines (Thimerosal),
see Centers for Disease Control
http://www.cdc.gov/vaccinesafety/updates/thimerosal.htm (last visited Sept. 25, 2008). The CDC
http://www.cdc.gov!vaccinesafety!updateslthimerosal.htrn
evidence of harm caused by the low doses of thimerosal in vaccines. Id.
maintains there is no scientific evidence
ld.
removal of thimerosal from childhood
Nevertheless, the CDC and other organizations recommended the removal
Use of
of
Recommendations Regarding
vaccines in 1999. Centers for Disease Control and Prevention, Recommendations
Regarding the Use
REP. 985,
& MORTALITY
MORTALITY WKLY REp.
Preservative,48 MORBIDITY
Vaccines
MORBIDITY &
Contain Thimerosal
Thimerosal As aa Preservative,
Vaccines That
That Contain
thimerosal has not been used as a
996-98 (1999).
influenza vaccines, thimerosal
(1999). With the exception of some influenza
since 2001.
preservative in routinely recommended
preservative
recommended childhood vaccines
vaccines since
2001. Centers for Disease Control and
supra.
Prevention,
Prevention, Mercury
Mercury and Vaccines, supra.
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preservative. 66 In effect, the Ferraris
Ferraris argued the vaccines
vaccines administered
administered
defectively designed
reasonable
to their son were defectively
because
safer
reasonable
7
7
available.
were
alternative designs
designs were available.
of
The adverse effects allegedly suffered by Stefan as a result of
8
8
of. The use of vaccines
vaccination, though rare, are not unheard of.
vaccines
throughout the world has undoubtedly led to some of the greatest
greatest
advancements
advancements in public health-the
health-the eradication
eradication of small pox, the
elimination of major disease outbreaks, and the prevention of
of
elimination
9
9
thousands of deaths annually. Despite these successes, a small but
significant
significant number
number of children suffer severe injuries each year as a
0
result of vaccination.'
vaccination. 10
What is quite unique about Stefan's case, however, is the treatment
it received in the Georgia
Georgia appellate courts in 2007 and 2008. In 2005,
2005,
the trial court granted summary
summary judgment in favor of the vaccine
manufacturers
manufacturers on the majority of the Ferraris'
Ferraris' claims, including their
design defect claims."
of
claims. II The Ferraris elected
elected to appeal. 1I22 In July of
13
decision.
novel
its
announced
Appeals
of
Court
2007, the Georgia
Appeals announced its novel decision. 13
On appeal, the vaccine manufacturers
law
manufacturers argued the Ferraris'
Ferraris' state law
design defect claims were preempted
Childhood
preempted by the National
National Childhood
Vaccine
pointed
Vaccine Injury Act of 1986 (the Vaccine Act or the Act), and pointed
4
14
to a series of holdings that support this position.
of
position.1 The Court of
6. Ferrari,
650 S.E.2d
S.E.2d at
at 588.
588.
Ferrari, 650
7. See id.
id. at 587.
8. See,
Elizabeth A. Breen,
Breen, Note,
Childhood Vaccine Injury
See. e.g., Elizabeth
Note, AA One Shot Deal:
Deal: The National
National Childhood
Injury
Act, 41
n.46 (1999-2000)
the approximately
approximately
41 WM. && MARY L. REv. 309, 314-15
314-15 n.46
(1999-2000) (explaining that of
of the
10,000
10,000 reports of adverse reactions received
received annually,
annually, less than fifteen percent describe serious
serious events or
reactions);
id at
reactions); id.
at 314 (stating more
more than
than 100
100 million
million doses
doses of
of vaccines are administered annually,
annually, yet
yet in
1997, fewer
fewer than
than one
hundred children
children died
died as
as a
a direct
result of immunization).
1997,
one hundred
direct result
Fragilityof
US. Vaccine Supply, 351
9. Frank A. Sloan et al.,
aI., The Fragility
of the U.S.
351 NEW ENG. J. MED. 2443,
2443 (2004).
10. See H.R. REp.
REP. No.
(1986), as reprinted
reprintedin 1986 U.S.C.C.A.N.
6344, 6345 ("While
NO. 99-908, atat 44 (1986),
V.S.C.CAN. 6344,6345
("While
most of
of the
the Nation's
Nation's children
enjoy greater
greater benefit
small but
significant
most
children enjoy
benefit from
from immunization
immunization programs,
programs, aa small
but significant
number have been
been gravely
gravely injured.").
11.
650 S.E.2d at 587.
II. Ferrari,
Ferrari, 650
587.
12.
12. Id.
/d. at
at 587.
13. See
id. at
at 590
590 (reversing
trial court's
court's grant
grant of
summary judgment
judgment in
in favor
favor of
the defendant
defendant
13.
See id.
(reversing the
the trial
of summary
of the
plaintiffs' design
vaccine manufacturers
manufacturers on
on the
the plaintiffs'
design defect claims
claims and
and holding
holding that the
the claims were not
preempted under federal
federal law).
law).
also Sykes
14. Id
Id. at
at 588; see also
Sykes v. Glaxo-SmithKline, 484
484 F. Supp. 2d
2d 289,
289, 302-03
302...{)3 (E.D. Pa.
Pa. 2007)
2007)
(holding
strict liability
liability and
(holding plaintiffs'
plaintiffs' strict
and negligent
negligent design
design defect claims
claims against vaccine manufacturers
manufacturers were
expressly preempted under
under the National Childhood
Childhood Vaccine
Vaccine Injury
Injury Act
Act of
of 1986);
1986); Blacknon
Blackmon v. Am.
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Appeals, however, found the
the preemption
preemption clause
clause at issue
issue in the
Appeals,
light of recent
recent precedent
precedent from the
Vaccine Act ambiguous, and in light
Vaccine
Ferraris' design
design defect
defect claims
claims were not
Supreme Court, held the Ferraris'
Supreme
15
preempted
In so doing, the
the Georgia Court of
of
preempted by federal
federal law.
law Y In
Appeals became
became the first court in the
the United
United States
States to interpret
interpret the
Appeals
Vaccine Act
Act to allow plaintiffs
plaintiffs to bring
bring design
design defect claims
claims against
against
Vaccine
vaccine manufacturers
manufacturers under
under traditional
traditional tort law theories
theories in state or
or
vaccine
16
federal courts. 16
vaccine manufacturers
manufacturers immediately
petition for
immediately filed a petition
The vaccine
17
of
Court
Georgia
the
of
Appeals. 17
certiorari, disputing the decision of the Georgia Court of Appeals.
certiorari,
In October
October of
of 2008,
2008, the Georgia
Georgia Supreme
Supreme Court
Court affirmed
affirmed the
different
albeit on different
conclusion reached
reached by the Court of Appeals, albeit
conclusion
18 Conflicting
Conflicting with the holdings
holdings of other state and federal
grounds. 18
courts throughout the country, the Georgia Supreme Court held that
courts
the National Childhood
Childhood Vaccine Injury Act does not preempt
preempt all
9
design defect claims
claims against
against manufacturers.
1 As a result, the Georgia
manufacturers. 19
design
Supreme Court's decision could open the door for design
design defect
defect suits
against vaccine
vaccine manufacturers
manufacturers by the parents
parents of2 children
children who have
0
2o
immunization.
from
effects
side
suffered adverse
adverse
effects from immunization.
By enacting
enacting the National
National Childhood
Childhood Vaccine Injury
Injury Act of 1986,
By
compensation for
Congress aimed to both ensure adequate
adequate and timely compensation
those suffering from vaccine related injuries and discourage vaccine

plaintiffs' negligent
(S.D. Tex. 2004)
Home Prods. Corp., 328
328 F. Supp. 2d 659, 666 (S.D.
2004) (holding plaintiffs'
negligent design
defect claims against
against several vaccine
vaccine manufacturers
manufacturers were barred by the National Childhood
Childhood Vaccine
Lederle Labs.,
Labs., 769 N.Y.S.2d
(finding that
Injury Act); Militrano v. Lederle
N.Y.S.2d 839, 845--46
845-46 (N.Y. Sup. Ct. 2003) (finding
against
1986 barred any design defect claims
Childhood Vaccine
claims brought against
the National Childhood
Vaccine Injury Act of 1986
vaccine manufacturing defendants).
15.
15. Ferrari,
Ferrari, 650 S.E.2d at 590.
Georgia
on Vaccine Suits;
Suits; Manufacturers
ManufacturersAsk
Court Hears
Hears Key Case
Case on
High Court
Ask Georgia
16. Alyson M. Palmer, High
Suits Aren't
Aren't Automatically
Automatically
Finding Vaccine Suits
Court Decision
Decision Finding
Court to Overturn
Overturn Lower Appeals Court
Supreme Court
Supreme
1.
21, 2008, at I.
REP. (Fulton County, Ga.), May 21,
Pre-emptedby Federal
Pre-empted
Federal Law, DAILY REp.
17. See Am. Home Prods. Corp. v. Ferrari, 668 S.E.2d 236, 237 (Ga. 2008).
17.
Vaccine Injury Act does not preempt
id. at 243 (holding that the National Childhood Vaccine
18. See id.
18.
preempt all
design defect claims against vaccine manufacturers).
Courts
Case; Conflicting
Court Backs
Backs Vaccine Suit in Autism Case;
19. See R. Robin McDonald, Court
Conflicting with Courts
Design Defect Claims",
Intend to "Pre-empt
"Pre-empt All
All Design
Congress Didn't
Didn't Intend
Country, Justices
Around the Country,
Justices Say Congress
7, 2008, at 1.
DAILY REP.
REp. (Fulton County, Ga.), Oct. 7,2008,
I.
Supreme Court's decision may allow the parents of children
Id. (noting
(noting that the Georgia Supreme
20. Id.
of
neurological effects are the result of
suffering from autism to bring suits in Georgia alleging that the neurological
vaccination).
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[Vol.

manufacturers
manufacturers from leaving the market or raising prices by insulating
2 1 This Note examines
them from certain product liability claims. 21
whether, in light of recent decisions by the Georgia appellate courts,
the Vaccine Act preempts a lawsuit for design defect claims against a
vaccine
vaccine manufacturer. Part I discusses the purposes of the Vaccine
Act, exploring the circumstances
circumstances that brought about its enactment and
22 Part II of
the subsequent
case
law that has come down in its wake. 22
of
subsequent
this Note analyzes
analyzes the Georgia Supreme
Supreme Court's decision in
American Home Products
specifically discusses
American
Products Corp.
Corp. v. Ferrari,
Ferrari, and specifically
whether the Court's holding that design defect liability claims under
under
traditional tort law are not preempted
by
the
Vaccine
Act
is
supported
preempted
23 Part III
by the text of the Vaccine
Vaccine Act and its legislative history.
history.23
inherent ambiguity
suggests that the inherent
ambiguity of the Vaccine Act's preemption
of design defect claims must be resolved in favor of vaccine
manufacturers by granting vaccines
"exceptional
manufacturers
vaccines the status of "exceptional
24
products.
products.,,24
Finally, this Note concludes that Congress's initial goals
in passing
passing the Vaccine Act are not met under the theory employed
employed in
Ferrari,
Ferrari, and that the purposes behind the Vaccine25Act mandate that
law. 25
by federal
are preempted
design defect claims
claims are
preempted by
federallaw.

21. See H.R. REp.
REP. No. 99-908, at 7 (1986),
6344, 6348 ("[T]wo
21.
(1986), as reprinted
reprinted in 1986 U.S.C.C.A.N.
U.S.C.C.A.N. 6344,6348
development of this legislation:
inadequacy-from both the
legislation: (a) the inadequacy-from
overriding concerns have led to the development
perspective
vaccine-injured persons as well as vaccine
vaccine manufacturers-of
manufacturers-of the current approach to
perspective of vaccine-injured
compensating
unpredictability of
of
compensating those who have been damaged
damaged by a vaccine; and (b) the instability and unpredictability
the childhood
childhood vaccine market.").
market.").
22. See discussion infra Part 1.
I.
23. See discussion infra Part
Part H.
II.
24. See discussion infra Part HI.
III.
25. See discussion infra
infra Part
HI and Conclusion.
Part III
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I.BACKGROUND
I.

American Home
Case Law Leading
A. A BriefHistory
A.
History of the Case
Leading to American
Products
Products Corp. v. Ferrari
Precedentand Adoption ofthe
1. American Immunization
1.
Immunization Precedent
NationalChildhood
Childhood Vaccine Injury Act of 1986
National
vaccination
immunization and vaccination
For more than a century, mandatory
mandatory immunization
United
programs have existed in various forms throughout the United
programs
26
26
States. Federal and state court decisions have consistently held it
of
within the police power of the states to require vaccination of
2
7
Vaccination mandates
citizens, provided the laws are reasonable.
reasonable?7 Vaccination
for children are particularly
particularly common, and courts have upheld them
unvaccinated children
denying unvaccinated
children access to public
even to the extent of denying
28
and private schools. For most American children, vaccination is
29
routine.29
childhood
Widespread
Widespread vaccination against common, yet deadly, childhood
"one of the most
infections
infections and diseases has been described
described as "one
spectacularly
spectacularly effective
effective public health initiatives this country has ever
ever
3
0
of
undertaken.
Vaccination prevents the death of thousands of
undertaken.,,,30 Vaccination
substantially reduces the effects resulting from
children
children each year, substantially
U.S. 11,
11, 38-39
26. Jacobson
Jacobson v. Massachusetts,
Massachusetts, 197 U.S.
38-39 (1905)
(\905) (holding a compulsory state statute,
statute,
which mandated
mandated vaccination
vaccination of all citizens
citizens against smallpox, a valid exercise
exercise of police power under the
the
Prophylaxis-MandatingHPV Vaccination
Politics,Parents
Parentsand
and Prophylaxis-Mandating
Constitution);
Constitution); see also R. Alta Charo,
Charo, Politics,
Vaccination
1905-06 (2007).
ENG. J.
J. MED. 1905,
1905, 1905-06
in the United
UnitedStates, 356 NEW ENG.
vaccination laws which
27. Jacobson,
Jacobson, 197 U.S. at 39 (explaining
(explaining the primary feature of compulsory
compulsory vaccination
which
reasonableness is an exemption
generally
generally imparts reasonableness
exemption clause for those with
with medical or contraindications
contraindications to
vaccination).
their vaccination programs.
vaccination). Today, all fifty states offer some form of exemption as part of their
ENG. J. MED. 2389,
NEw ENG.
andPolitics
Compulsory HPV Vaccination,
James
Colgrove, The Ethics
Ethics and
Politics of Compulsory
Vaccination, 355 NEW
James Colgrove,
2390 (2006). School
School immunization
immunization laws in every
every state grant exemptions
exemptions for children
children with medical
contraindications
Id. Additionally,
Additionally, forty-eight states allow religious exemptions for
contraindications to immunizations. Id.
immunization. Id. A growing number of states, currently
people
currently
people with sincere religious opposition
opposition to immunization.
twenty
twenty in total, also grant exemptions for parents who
who claim philosophical
philosophical convictions against
Id.
immunization. Id.
(finding a San Antonio city ordinance,
174, 176-77 (1922)
(1922) (finding
28. Zucht v. King, 260 U.S. 174,176-77
ordinance, which denied
denied
unvaccinated children,
admission
admission to both public and private schools
schools to unvaccinated
children, a valid exercise of police power).
children must show proof of immunity to enroll
29. According
According to the CDC, by the age of five, when children
in public schools, the rate of vaccination compliance
compliance climbs to more than 95%. Pauline
Pauline Self, Note, The
WOMEN'S LJ.
L.J. 149, 161 (2008).
Necessary or Evil?, 19 HAsTINGS
HASTINGS WOMEN'S
HPV Vaccination:
Vaccination: Necessary
6344,6345.
NO. 99-908,
99-908, at 4 (1986),
(1986), as reprinted
REP. No.
30. H.R. REp.
reprinted in 1986 U.S.C.C.A.N.
U.S.C.C.A.N. 6344,
6345.
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disease-it even led to the eradication
eradication of small pOX.
pox.3311 In the early
1980s, however, the country's ability to continue
continue supporting wide32 Litigation by children
scale vaccination
vaccination of children was in jeopardy. 32
children
suffering
suffering injuries
injuries from vaccines increased dramatically, causing
vaccine
vaccine manufacturers
manufacturers to raise prices significantly
significantly or leave the
33 This resulted in vaccine shortages and an
market altogether. 33
34
children. 34
all American
inability to ensure vaccine availability
availability to
to all
American children.
Congress sought to address this looming problem by enacting the
35
National Childhood Vaccine
Vaccine Injury
Injury Act of 1986. 35
The goal of the Vaccine Act was twofold:
twofold: (1) ensure
ensure those
compensation in a
suffering injures as a result of vaccination receive compensation
manner that is more predictable, cost-efficient, and timely than the
of
traditional tort system, and (2) free manufacturers
manufacturers from the threat of
large, uncertain tort liability, and thereby encourage
them
to
remain
encourage
remain
Vaccine Act established
established the
in the market and keep prices low. 36 The Vaccine
National
Compensation Program,
National Childhood Vaccine
Vaccine Injury Compensation
providing a unique avenue of recovery for those suffering injury or

31. Sloan et aI.,
al., supra
31.
supra note 9, at 2443.
2443.
REP. No. 99-908,
99-908, at 4 (describing how
how previously unrecognized
unrecognized injuries associated with
32. H.R. REp.
vaccines were becoming widely known, leading injured parties to seek redress and financial relief
relief from
the tort system
system in increasing numbers).
manufacturers of the diphtheria,
33. For example, in 1978, only one lawsuit was filed against manufacturers
1985, however, DTP vaccine
tetanus, pertussis (DTP) vaccine. In 1985,
vaccine manufacturers
manufacturers faced 219 lawsuits.
Militrano v. Lederle
Lederle Labs., 769 N.Y.S.2d
N.Y.S.2d 839,
839, 843
843 (N.Y. Sup. Ct. 2003). Additionally,
Additionally, the costs
associated with defending
defending these lawsuits and maintaining sufficient
sufficient insurance was the primary factor in
the increased
increased cost of vaccines.
vaccines. Id.
Id. The average price of the DTP vaccine
vaccine in 1984
1984 was eleven
eleven cents per
dose, whereas
of a dose was
$11.40. Shackil v. Lederle
511, 523 (N.J.
whereas in 1986 the price ofa
was $11.40.
Lederle Labs.,
Labs., 561 A.2d
A.2d 511,
1989). Eight dollars in this price
price increase was attributed to the cost of insurance
insurance alone. Id.
Id. Insurance
costs were also a significant
producing DTP,
significant factor in the decrease in the number of manufacturers producing
which dropped from five in 1972
Id.
1972 to two by 1984. Id.
34. See Randall
Dej6 VII
Vu All Over Again? The National
National Childhood
Childhood Vaccine Injury
Injury
Randall B. Keiser, Deja
Compensation
1986, 47 FOOD &
and
Compensation Act of J986,
& DRUG L.J. 15,
IS, 16 (1992)
(1992) (explaining that increased costs and
decreased
corresponding
decreased availability
availability of vaccines caused
caused levels of immunization to drop, resulting in a corresponding
increase
U.S. during
1980s).
increase in the incidence of disease in some areas
areas of the V.S.
during the early 1980s).
U.S.C. §§
§§ 300aa-\
300aa-I to -34 (2000). The Act is divided into two parts. Part I of the Act
35.
35. 42 V.S.C.
establishes
vaccine-related
establishes the National Vaccine Program, which is charged
charged with overseeing
overseeing federal vaccine-related
research,
research, testing, licensing, production, and distribution, and improving the nation's immunization
immunization
programs.
Id §§
§§ 300aa-l
Compensation
programs.Id.
300aa-1 to -6. Part II of the Act establishes
establishes the National
National Vaccine
Vaccine Injury
Injury Compensation
Program, which
which includes the creation
creation of a vaccine
vaccine injury compensation
compensation trust fund and
and outlines the
§§ 300aa-1O
300aa-10 to
procedures, requirements, and conditions under which injured parties may recover. Id.
Jd. §§
to-34.
36.
as reprinted
in 1986
U.S.C.C.A.N. 6344, 6348.
36. See H.R. REP.
REp. No. 99-908,
99-908, at 7, as
reprinted in
1986 V.S.C.C.A.N.
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37 Under
death as a result of vaccination. 37
Under the Act's procedural
procedural
requirements, an injured individual
compensation must first
requirements,
individual seeking
seeking compensation
38
file a petition in the Court of Federal Claims. 38
The petitioner does
not have the burden of proving fault or causation;39
causation; 39 he need only
show that he received a vaccine covered
covered by the Act and then suffered
certain symptoms
symptoms or side effects within a defined period of time to
40 Awards are drawn
make out a prima facie case for compensation. 4o
from a fund financed by an excise tax on each vaccine dose. 441'
The Vaccine Act prohibits an injured individual
individual from filing a civil
action for damages
damages before first filing a petition
petition and seeking
seeking judgment
judgment
42
42
from the Court of Federal Claims. The petitioner
petitioner may then either
accept the Federal Claims Court's judgment
judgment (and any award) and
43
rights, or reject the judgment
abandon his tort rights,43
judgment and retain his tort
judgment of the Court of
of
rights. 44 If a plaintiff elects to reject the judgment
Federal Claims, he may pursue his tort law claims in state or federal
45
Vaccine Act.
in the
spelled out
court, subject to certain limitations
limitations spelled
out in
the Vaccine
Act. 45
In § 300aa-22(a)
300aa-22(a) the Act specifically
specifically provides
provides that once a claimant
Federal Claims process,
process, "State
"State law shall
shall
opts out of the Court of Federal
apply to a civil action brought for damages for a vaccine-related
vaccine-related

300aa-10(a).
37. 42 U.S.C. § 300aa-\O(a).
300aa-I l(a)(2)(A) provides the following:
38. Section 300aa-ll(a)(2)(A)
$1,000 or
No person may
may bring aa civil action for
for damages
damages in an
an amount
amount greater than $1,000
or in an
an
unspecified
unspecified amount against aa vaccine administrator or manufacturer
manufacturer in aa State or Federal
Federal
court
court for damages arising from aa vaccine-related
vaccine-related injury or death associated
associated with
with the
the
administration of
vaccine after
after October
October I,
1, 1988,
1988, and
and no
such court
court may
may award
award damages
administration
of aa vaccine
no such
damages
in
$1,000 in
in an amount greater than
than $1,000
in aa civil action
action for damages
damages for such aa vaccine-related
injury
or death,
unless a
a petition
filed..,
injury or
death, unless
petition has
has been
been filed
... for compensation under
under the Program
Program
for
for such injury or death.
39. Id.
§§ 300aa-l
-14; see also Shalala
Shalala v.
Id. §§
300aa-11I toto -14;
v. Whitecotton,
Whitecotton, 514
514 U.S.
U.S. 268,
268, 270
270 (1995)
(1995) (explaining
(explaining
that aa claimant is eligible
eligible for compensation by
by introducing
introducing proof
proof of
of actual
actual causation, but alternatively,
compensation can
can also
also be
be awarded if the
the claimant meets the requirements
requirements of
of the
the Vaccine Injury Table
without proving causation).
300aa-I ito-14.
40. 42 U.S.C. §§ 300aa-ll
to -14.
Id.;
41. Id.;
see also
also I.R.C. § 9510 (2006) (establishing
(establishing procedures
procedures for
for maintenance
maintenance of
of the
the fund).
300aa-ll.
42. 42 U.S.C.
U.S.C. § 300aa-11.
43. IfIf the claimant elects to
to accept compensation and abandon
abandon his tort rights, the
the Act transfers
transfers these
these
rights to
federal government
government via
via subrogation.
subrogation. 42
42 U.S.C. § 300aa-17.
rights
to the
the federal
Id.;
see also
300aa-i 1(a)(2)(A)(i), 300aa-21(b) (stating
44. !d.;
also §§
§§ 300aa-ll(a)(2)(A)(i),
(stating the
the claimant
claimant may reject
reject the judgment
judgment
of the Court
Court of Federal
Federal Claims and
and retain
retain his tort
tort rights; alternatively,
alternatively, the
the claimant
claimant may keep his tort
rights by
by withdrawing
withdrawing his petition if the Court
Court moves
moves too slowly or aa decision
decision isis unreasonably delayed).
delayed).
300aa-21.
45. See id.
id. § 300aa-21.
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injury
or death.'A
statement, however,
followed by
caveat
injury or
death.',466 This
This statement,
however, is
is followed
by aa caveat
in
300aa-22(b): "No
manufacturer shall
shall be
liable in
in aa civil
civil
in § 300aa-22(b):
"No vaccine
vaccine manufacturer
be liable
action
damages arising
arising from
from aa vaccine-related
vaccine-related injury
injury or
death...
action for
for damages
or death
...
if
the
injury
or
death
resulted
from
side
effects
that
were
unavoidable
if the injury or death resulted from side effects that were unavoidable
even
the vaccine
properly prepared
was accompanied
accompanied
even though
though the
vaccine was
was properly
prepared and
and was
'
7
by
and warnings.
A In effect,
effect, this
section of
of the
by proper
proper directions
directions and
warnings.',47
this section
the
Vaccine
Act places
places limits
limits on
on aa potential
potential plaintiffs
right to
to bring
bring aa
Vaccine Act
plaintiffs right
48
design defect
against aa vaccine
vaccine manufacturer.
design
defect claim
claim against
manufacturer. 48 Congress
Congress
modeled
subsection (b)
(b) specifically
after comment
comment k to
to section
402A
modeled subsection
specifically after
section 402A
49
49
of the
the Restatement
Restatement (Second)
(Second) of
of Torts.
Thus,
it is
is clear
of
Torts.
Thus, it
clear the
the Vaccine
Vaccine
Act
preempts state
law to
to some
some extent,
but still
still expressly
expressly reserves
reserves aa
Act preempts
state law
extent, but
50
courts.
state
for
role
role for state courts. 50
2. Struggling
Interpretationof
of§
Struggling to Apply
Apply the Vaccine Act: Interpretation
§ 300aa300aa22(b)
22 (b)
Subsequent
courts interpreting
interpreting the
Vaccine Act
Act have
have struggled
to
Subsequent courts
the Vaccine
struggled to
determine the
which traditional
traditional tort
law remedies
remedies for
design
determine
the extent
extent to
to which
tort law
for design
51
defect claims
claims are
are preempted
the language
defect
preempted by
by the
language of
of § 300aa-22(b).
300aa-22(b).51
52
is ambiguous.
face, is
the limitation,
that the
declared that
have declared
Courts have
Courts
limitation, on
on its
its face,
ambiguous. 52
46. See id. § 300aa-22(a).
300aa-22(a).
Id.§ 300aa-22(b)(1)
47. /d.
300aa-22(b)(I) (emphasis
(emphasis added). Additionally, § 300aa-22(b)(2)
300aa-22(b)(2) presumes that a vaccine is
accompanied by proper warnings
complied with all
accompanied
warnings and directions so long as the manufacturer
manufacturer complied
applicable requirements under the Federal Food, Drug
Drug and Cosmetic
300aa-22(c) states
applicable
Cosmetic Act. Finally, § 300aa-22(c)
that no vaccine manufacturer
manufacturer will be held liable in a civil action for failing to provide direct warnings
wamings to
the injured
injured party.
supranote 34, at 30.
48. Keiser, supra
REP. No. 99-908, at 25-26 (1986),
(1986), as
as reprinted
reprinted in 1986 V.S.C.C.A.N.
U.S.C.C.A.N. 6344, 6366
49. See H.R. REp.
6366
(stating
(stating that § 300aa-22(b)
300aa-22(b) sets forth the principle
principle contained in comment
comment k of Section 402A of the
Restatement
(Second) of Torts).
Restatement (Second)
50. 42 V.S.C.
U.S.C. § 300aa-22(b);
1, 3
3 (1st Cir. 1994)
300aa-22(b); see also Schafer v. Am.
Am. Cyanamid
Cyanamid Co., 20 F.3d I,
("[The
("[T]he Act modifies, but does not eliminate,
eliminate, the traditional
traditional tort system, which Congress understood
understood to
provide important
important incentives
incentives for the safe manufacture and distribution of vaccines.").
51.
51. See Bruesewitz v. Wyeth, Inc.,
Inc., 508
508 F. Supp. 2d 430,
430, 440 (E.D.
(E.D. Pa. 2007)
2007) (noting the two
alternative
manufacturers); Sykes v. Glaxoalternative interpretations put forth by plaintiffs and defendant
defendant manufacturers);
GlaxoSmithKline, 484 F. Supp. 2d 289, 299 (E.D. Pa. 2007)
2007) (finding § 300aa-22(b)
300aa-22(b) has two "plausible"
"plausible"
meanings and noting that the plain text of the Vaccine
Vaccine Act does not resolve the proper interpretation);
Blackmon v. Am. Home Prods. Corp., 328 F. Supp. 2d 659, 663 (S.D. Tex. 2004) (discussing
(discussing two
possible
300aa-22(b)); Am. Home Prods. Corp. v. Ferrari,
interpretations of § 300aa-22(b»;
possible conflicting
conflicting interpretations
Ferrari, 668 S.E.2d
to
236, 239 (Ga. 2008)
2008) (acknowledging
(acknowledging that two alternative, plausible
plausible readings
readings exist with regard to
preemption
300aa-22(b)); Militrano
preemption under § 300aa-22(b»;
Militrano v. Lederle
Lederle Labs., 769 N.Y.S.2d 839, 843 (N.Y. Sup. Ct.
2003) (stating
(stating that on its face, the meaning
meaning of § 300aa-22(b)
300aa-22(b) "is not entirely clear").
clear").
Militrano,769 N.Y.S.2d
52. Militrano,
N.Y.S.2d at 843.
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In
In doing so, two plausible readings of the section have been
first possible reading posits that any injury caused
53 The fIrst
caused
suggested. 53
by a vaccine covered
covered under the Act is deemed "unavoidable"
"unavoidable" as a
matter of law, provided the vaccine was properly prepared and
54 This reading of the statute
accompanied by adequate
adequate warnings. 54
essentially
premised on a
essentially provides a complete
complete bar to state tort suits premised
55 Alternatively, the second possible reading
of
reading of
design defect theory. 55
the limitation posits that the section
section could be read as barring design
defect claims only where the side effects are determined, on a caseby-case
56 This reading permits juries in
by-case basis, to be unavoidable.
unavoidable.56
individual cases to determine
determine whether
whether a vaccine could have been
57
designed better so as to avoid the injury suffered.57
To resolve the ambiguity
ambiguity and decide which of the two
interpretations is accurate, courts have looked
Congress's
interpretations
looked to Congress's
legislative intent in enacting the Vaccine
Vaccine Act. 58 Most courts believe
strongly supports a construction that
the legislative
legislative history of the Act strongly

See, e.g.,
53. See,
e.g., Blackmon, 328 F. Supp. 2d at 663.
54. See, e.g., Sykes, 484 F. Supp. 2d at 299 ("[D]efendants
("[D]efendants constme
construe this section of the Vaccine
Vaccine Act
Act
vaccine-related injuries so long as the vaccine
to impose
impose a total bar on design defect claims
claims arising from vaccine-related
specifications.").
was produced
produced in accordance
accordance with FDA-approved specifications.").
interpretation advocated
See, e.g.,
e.g., Sykes,
55. Not surprisingly, this is the interpretation
advocated by vaccine
vaccine manufacturers. See,
484
484 F. Supp. 2d at 299; Blackmon, 328 F. Supp. 2d at 663; Ferrari,
Ferrari, 668
668 S.E.2d at 237;
237; Militrano,
Militrano, 769
N.Y.S.2d
interpretation is attractive to manufacturers
manufacturers because
N.Y.S.2d at 843-44. This
This interpretation
because it implies that Congress
Congress
entrusted the determination
safe to the expertise of federal health
determination of whether a vaccine design is safe
agencies, rather than juries. Sykes, 484
484 F. Supp. 2d at 299.
56. See,
See, e.g., Militrano,
Militrano, 769 N.Y.S.2d at 844 (explaining
case-by-case basis
(explaining that determination on a case-by-case
would involve
involve an inquiry into whether a covered vaccine could have been designed better so as to avoid
the injury being
being suffered
suffered by the claimant).
interpretation argued for by plaintiffs.
plaintiffs. See,
See, e.g., Sykes, 484 F. Supp. 2d at
57. This, of course, is the interpretation
299; Blackmon, 328 F. Supp. 2d at 663; Ferrari,
Ferrari, 668 S.E.2d at 237; Militrano,
Militrano, 769
769 N.Y.S.2d at 844.
interpretation is asserted
to
This interpretation
asserted by plaintiffs because
because it allows
allows a jury, rather than a federal agency,
agency, to
determine whether a particular
particular side effect
effect was unavoidable. Blackmon, 328 F. Supp. 2d at 665. A
plaintiff can demonstrate
demonstrate the design defect
defect was not unavoidable
unavoidable by showing that a reasonable alternative
alternative
design was feasible. Id.
Id.
("1 will look at the legislative history
58. See Sykes,
Sykes, 484 F. Supp. 2d at 299 ("I
history of the Act and any other
other
relevant extrinsic material
material to decipher
decipher Congress's intent
intent in enacting 42 U.S.C. § 300aa-22(b)(l).");
300aa-22(bXI).");
Blackmaon, 328 F. Supp. 2d at 664 ("The legislative
300aa-22(b)
Blackmon,
legislative history
history also supports a construction of § 300aa-22(b)
that would bar all defective design claims under the conditions
Militrano, 769
conditions outlined
outlined in the statute."); Militrano,
N.Y.S.2d
("Resolution of these competing
interpretations requires a tripartite
N.
Y.S.2d at 844 ("Resolution
competing interpretations
tripartite analysis of the
legislative
legislative history of the Act, the Restatement (Second)
(Second) of Torts, and the case law that existed
existed at the time
the Act was enacted.");
Oklahoma v. New
221, 235 n.5 (1991),
(1991), in which the
New Mexico,
Mexico, 501 U.S. 221,
enacted."); see also Oklahoma
U.S. Supreme
Supreme Court
Court asserts that when interpreting an ambiguous statute, the Court has consistently
examined legislative history and other extrinsic
extrinsic material.
material.
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would bar all defective
defective design claims under state law. 59 For example,
they often point to a passage in the Report of the Committee on
Energy and Commerce that states the following:
Vaccine-injured persons will now have an appealing alternative
Vaccine-injured
to the tort system. Accordingly,
Accordingly, if they cannot demonstrate under
applicable
applicable law either that a vaccine was improperly prepared
prepared or
that it was accompanied
accompanied by improper directions or inadequate
inadequate
warnings [they] should pursue recompense in the compensation
compensation
6
the tort
system, not the
tort system.
system. 600

Thus, for several
several years,
years, courts throughout the United
United States that
have decided the issue applied the first reading
reading of the statute-that
injuries
caused
by
covered
vaccines
are
unavoidable as a matter of
injuries
covered
of
law-and
design defect
law-and dismissed state tort law claims 6premised
on
Act. 611
theories
theories as preempted
preempted by
by the
the Vaccine
Vaccine ACt.
Everything Changes:
Changes: The Georgia
GeorgiaAppellate Courts
Courts Decide
3. Everything
Decide
Ferrari
Ferrari
opinion in
In 2007, the Georgia Court of Appeals
Appeals released its OpInIOn
62
Ferrari
v. American
American Home Products
Corp. In its analysis, the Court
Ferrari v.
Products COrp.62
of Appeals
relied
heavily
upon
a
case
Appeals
recently decided by the U.S.
U.S.
63
Bates examined
examined
Supreme Court, Bates v. Dow Agrosciences LLC. 63
different federal
federal preemption
preemption of state tort law claims under a different
act, the Federal Insecticide,
Insecticide, Fungicide, and Rodenticide
Rodenticide Act
E.g., Mi1itrano
Militrano v. Lederle Labs., 810 N.Y.S.2d
N.Y.S.2d 506,
59. E.g.,
506, 508 (N.Y. App. Div. 2006) (noting the
the
legislative history suggests that Congress clearly
generally
clearly intended to bar all design defect claims). See generally
REP. No. 99-908, at 26 (1986),
reprintedin 1986 U.S.C.C.A.N.
6344, 6367 (explaining that it
H.R. REp.
(1986), as reprinted
U.S.C.C.A.N. 6344,6367
would be very difficult for a jury, upon seeing a child who has been injured
injured by a vaccine, to find in favor
favor
of the manufacturer,
manufacturer, even if the vaccine
vaccine had been made as safely as anyone
anyone could reasonably
reasonably have
expected).
REP. No. 99-908,
U.S.C.C.A.N. 6344, 6367.
60. H.R. REp.
99-908, at 26, as reprinted
reprinted in 1986 U.S.C.C.A.N.
61. See Ferrari v. Am. Home Prods. Corp., 650 S.E.2d
S.E.2d 585, 588 (Ga. Ct. App. 2007)
61.
2007) ("Only
("Only a
U.S.C. § 300aa-22, and
handful of courts have addressed
addressed the scope of the preemption
preemption clause
clause found in 42 U.S.C.
and
each has concluded,
concluded, after examining the legislative
legislative history of the Vaccine Act, that the issue of whether
whether
side effects
effects are 'unavoidable'
'unavoidable' cannot
canoot be litigated in civil actions.").
62. 650 S.E.2d
S.E.2d 585 (Ga. Ct. App. 2007).
63. Bates
Bates v. Dow Agrosciences
Agrosciences LLC, 544 U.S.
U.S. 431 (2005).
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64
(FIFRA).
(FIFRA).64
The portion of FIFRA
FIFRA at issue in Bates was declared
declared
65
meaning.
plausible
one
only
to
susceptible
and susceptible to only one plausible meaning. 65
clear, unambiguous,
unambiguous, and
However, the
the Court noted
noted that when a statute
statute is
is ambiguous,
ambiguous, courts
have a duty to accept the reading
that
disfavors
reading
disfavors preemption. 66 The
Bates changed
Georgia Court of Appeals opined that Bates
changed traditional
preemption
analysis, thus
altering the
the viability
viability of vaccine
preemption analysis,
thus drastically
drastically altering
67
design defect claims in state
state tort proceedings.
design
proceedings. The Court of Appeals
determined
that
(1)
there
is
no
determined that (1) there is no longer aa rebuttable
rebuttable presumption
presumption
to accept
against preemption,
preemption, but aa duty to
against
accept the reading of an express
preemption
that disfavors
preemption; 6 8 and (2) preemption
preemption
preemption statute that
disfavors preemption;68
analysis ends
ends with
with an
an examination
language alone and
analysis
examination of the statutory
statutory language
69
consultation of legislative history.
Because the Vaccine
no consultation
history.69 Because
Vaccine Act is
is
susceptible to two plausible readings, courts have a duty to accept the
susceptible
reading that
disfavors preemption-despite
any legislative
legislative intent
reading
that disfavors
preemption--<iespite any
intent
70
indicating the contrary.70
contrary. Thus, under
plaintiffs' design
indicating
under this analysis, plaintiffs'
defect
claims
against
vaccine
manufacturers
are
not
preempted
by the
the
defect claims against vaccine manufacturers are not preempted by
7711
Vaccine Act.
Vaccine
ACt.

64. 7 U.S.C. § 136 (2000).
Bates, 544 U.S. at 448-49 (noting there
alternative interpretation of the statute
65. Bates,
there was no plausible
plausible alternative
at issue, thus implying the statute was unambiguous).
unambiguous).
Id. at 449 ("Even if Dow had offered us a plausible alternative reading of § 136v(b
136v(b)-indeed,
66. Id.
}--indeed,
alternative were
even if its alternative
were just as plausible as our reading of that text-we would
would nevertheless
nevertheless have a
duty to accept
accept the reading that disfavors pre-emption....
pre-emption. . .. In areas of traditional state regulation, we
assume that aa federal statute has not supplanted
supplanted state law unless Congress has made such
such an intention
'clear
and manifest.'"
manifest."' (quoting
N.Y. State
State Conference
Conference of
Blue Cross
& Blue
Blue Shield Plans v. Travelers
'clear and
(quoting N.Y.
of Blue
Cross &
Travelers
Ins. Co., 514 U.S. 645, 655 (1995))).
(1995»).
Ferrari,650 S.E.2d
67. Ferrari,
S.E.2d at 589.
68. In other words, if a statute is ambiguous in any way, the court must apply the interpretation
interpretation that
disfavors preemption
preemption and allows state law causes of action to proceed. Id.
Id.
Legislative history, as well as any other relevant
69. Legislative
relevant extrinsic materials, cannot be consulted under
Bates. Id.
Id.
the court of appeals
appeals interpretation of Bates.
70. The court of appeals recognized
recognized the novelty of the decision it fashioned:
While this result differs
differs from that reached by other courts addressing the preemptive
effect
effect of the Vaccine
Vaccine Act, none of those courts addressed
addressed the impact
impact of Bates on the
analysis
preemption clauses. We
analysis of ambiguous express
express preemption
We recognize that this result is
anomalous
anomalous given
given the clear legislative history to the contrary, but we are constrained to
follow the Supreme Court's explicit
Bates.
explicit guidance in Bates.
Id. at 590.
Id.
71.
71. According to the court of appeals,
appeals, because
because two plausible, alternative readings of the Vaccine Act
to
exist, and one of these readings disfavors federal preemption of state law tort claims, there is a duty to
accept this interpretation, and thereby allow design defect
Id.
defect claims to proceed
proceed in state courts. Id.
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In October
October of 2008, the Georgia Supreme Court affirmed the Court
of Appeals
opinion. 72 The reasoning
Appeals decision in a unanimous opinion.72
reasoning relied
on by the Georgia Supreme
Supreme Court, however, was quite different
different than
Supreme
that employed by the Court of Appeals. First, the Georgia Supreme
Court determined that the Court of Appeals erred in holding that
Bates precludes
precludes the use of legislative history in preemption
73 Rather than drastically altering the traditional preemption
analysis. 73
preemption
analysis, as the Court of Appeals
Appeals advocated,
advocated, Bates instead offered a
strong affirmation of the presumption
presumption against preemption in products
liability cases, and demonstrated that this presumption applies
except
applies except
74
circumstances.
of
in the narrowest of circumstances. 74
The Georgia Supreme Court then proceeded
proceeded with a far-reaching
of
both
the
specific
examination
language
of the Vaccine
Vaccine Act and its
examination
75
legislative
history. The court examined
comment k to section 402A
examined comment
402A
legislative history.75
of the Restatement
Restatement (Second)
(Second) of Torts and determined
determined that the
majority
so
jurisdictions that have adopted the comment
comment have done so
majority of jurisdictions
on a case-by-case
case-by-case basis, electing
electing not to grant blanket immunity
immunity to
76 Furthermore, the Georgia Supreme Court
product
Furthermore,
Georgia Supreme
product manufacturers.
manufacturers. 76
interpreted the legislative
legislative reports behind the Vaccine
Vaccine Act's passage
passage to
of
leave open the possibility of design
design defect suits, refuting the claims of
77
contrary.
the
to
history
legislative
clear
is
there
that
courts
other
clear legislative history to the contrary.77
The Georgia Supreme Court's decision allows plaintiffs, including
including
the Ferraris, to bring design defect claims against vaccine
manufacturers with juries deciding, on a case-by-case
whether
manufacturers
case-by-case basis, whether
alternative
a particular
particular side effect was unavoidable
unavoidable or if a safer alternative
78
vaccine.
the
design existed for
78
for the vaccine.

72.

Am. Home
Home Prods. Corp.
Corp. v. Ferrari, 668 S.E.2d
S.E.2d 234
234 (Ga. 2008).
Id. at
73. Id.
at 238-39 ("[T]he
("[T]he Court of Appeals took 'one part
part of
of the
the Bates ruling out of
of its context,
context, and
[gave] itit broader
broader scope than isis appropriate."'
appropriate.'" (quoting
(quoting Bruesewitz v. Wyeth, 508 F.F. Supp. 2d 430,
430, 444
Pa. 2007»).
2007))).
(E.D. Pa
Id. at 239.
74. Id.
75. Id.
Id. at
at 238-43.
238-43.
76. Id. at 239
239 (concluding most
most states that adopted
adopted comment k, including
including Georgia,
Georgia, did so
so in aa limited
manner).
manner).
Id. at
77. Id.
at 243-44
243-44 (citing
(citing cases that
that admit
admit it isis possible Congress
Congress left
left open
open the possibility
possibility of design
design
defect
defect claims for vaccines
vaccines covered
covered by the Act).
Ferrari,668
78. Ferrari,
668 S.E.2d atat 243.
243.
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B. The Importance
Defining the Scope of Federal
Preemption
B.
Importance ofDefining
Federal Preemption
Under the Vaccine Act
Act
Under

This Note focuses on the extent to which federal law, and the
Vaccine Act specifically, preempts
preempts a state law tort claim against a
vaccine manufacturer
manufacturer for design defects, and whether the Georgia
Georgia
Supreme Court's decision in Ferrari
Ferrari correctly
correctly determined
determined that
Congress did not intend to preempt all design defect claims against
vaccine manufacturers
manufacturers with the passage of the Vaccine Act. The
resolution of this question has significant ramifications
ramifications for vaccine
manufacturers,
potential
tort
plaintiffs,
and
the American
manufacturers, potential
plaintiffs,
American public as a
79
whole. An interpretation
interpretation of the Vaccine
Vaccine Act that opens up vaccine
vaccine
manufacturers
manufacturers to potential
potential liability for design defects will likely lead
to an increase
increase in litigation, and a return to the days when both
plaintiffs and defendants faced uncertain and unpredictable
unpredictable results in
the traditional tort system. Furthermore, the specter of large and
uncertain liability could
could once again result in significant price
of
increases for vaccines-or
vaccines-or even worse, the complete
complete unavailability of
some vaccines.
AND LEGISLATIVE
II. ANALYZING
ANALYZING THE TEXT AND
LEGISLATNE
HISTORY
HISTORY OF § 300AA-22(B)(1)
300AA-22(B)(1)

Only a handful of courts have examined
examined whether
whether the Vaccine
Vaccine Act
preempts
preempts all claims that a vaccine was defectively designed.88o° With
the exception
Appeals and the Georgia
exception of the Georgia Court of Appeals
79. Elizabeth
Hazards,WASH.
TIMES (D.C.),
(D.C.), June 8,
8,2008,
Elizabeth A. Yi, Editorial, Vaccine Lawsuit Hazards,
WASH. TiMES
2008, at B5.
80. At the time the Georgia
Supreme Court opinion was issued, two federal District Courts and two
Georgia Supreme
states
states other than
than Georgia
Georgia had examined the question
question in published opinions. The United
United States District
District
Court for the Eastern
Pennsylvania first explored the question in Sykes
v. Glaxo-SmithKline in
Eastern District of Pennsylvania
Sykes v.
March
2007, 484 F. Supp. 2d 289 (E.D. Pa. 2007),
Inc. in August
March of
of2007,
2007), and again in Bruesewitz v. Wyeth, Inc.
August
of 2007. 508 F. Supp. 2d 430 (E.D.
(E.D. Pa. 2007). The United States District
District Court for the Southern District
District
of Texas examined
examined the issue in Blackmon v. American Home Products
Products Corp. in 2004. 328 F. Supp. 2d
(S.D. Tex. 2004). In
preemption
659 (S.D.
In 2003,
2003, a New York
York state trial court explored vaccine design defect preemption
in Militrano
Militrano v. Lederle Laboratories.
Laboratories. 769 N.Y.S.2d
N.Y.S.2d 839 (N.Y. Sup. Ct. 2003).
2003). Most recently, the
Philadelphia
Wright v. Aventis Pasteur,
Pasteur,Inc., No.
Philadelphia Court of Common Pleas tackled the issue in 2008 in Wright
3861, 2008 Phila. Ct. Com. P1.
3861,2008
PI. LEXIS 221 (Phila.
(phila. Ct. Com. Pl.
PI. Aug. 27, 2008). Following the Georgia
Ferrariopinion, the Third
Supreme Court's Ferrari
Third Circuit
Circuit examined the issue and upheld the district court's
court's
dismissal of plaintiffs'
251
plaintiffs' design
design defect claims in Bruesewitz.
Bruesewitz. Bruesewitz
Bruesewitz v. Wyeth, Inc., 561 F.3d 233,
233,251
(3d Cir. 2009).
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Supreme Court, every court that has examined the question held that
Act.881 Like
all design defects claims are preempted
preempted by the Vaccine ACt.
previously analyzed the issue, however, the
each of the courts that previously
preemption analysis
Georgia Supreme Court employed a traditional preemption
82
approved by the United States Supreme Court.
COurt. The court's analysis
analysis
began with an extensive examination of the preemptive text of the
Vaccine Act, found in § 300aa-22(b), which is based directly on
83
Torts. 83
of Torts.
(Second) of
Restatement (Second)
the Restatement
402A of
of the
comment k to section 402A
examination of the legislative
The analysis then proceeded
proceeded with an examination
legislative
associated with the Vaccine Act's passage to decipher
decipher
history associated
84
statute.
the
enacting
in enacting the statute. 84
Congress's
Congress's purpose
purpose in

A. Defining
TraditionalPreemption
PreemptionAnalysis
Defining Traditional
Under the Supremacy
Supremacy Clause of the United States Constitution,
state laws that are in opposition
opposition to or interfere with federal laws on a
particular subject are unenforceable,
unenforceable, and thus preempted
particular
preempted by and
and
85
85
secondary
secondary to federal law. The defendant vaccine manufacturers
manufacturers
argue that the Vaccine Act expressly
expressly preempts design defect claims
86
by plaintiffs.86
Express
Express preemption
preemption exists
exists when Congress
Congress expressly
expressly
states in a statute
preempted by federal law.87
statute that state law is preempted
87 It is
clear
300aa-22(b) that Congress
Congress intended to
clear from the language
language of § 300aa-22(b)
81.
81. See Bruesewitz, 508
508 F. Supp. 2d at 446;
446; Sykes, 484
484 F. Supp. 2d at 303;
303; Blackmon, 328 F. Supp.
Supp.
2d at 666; Militrano,
P1. LEXIS 221,
Mililrano, 769 N.Y.S.2d at 845-46; Wright, 2008 Phila. Ct. Com. PI.
221, at *33;
*33; see
also
also Bruesewitz,
Bruesewitz, 561 F.3d at 251 (rendering decision
decision following the
the opinions from the Georgia
Georgia appellate
appellate
courts). But see Ferrari,
Ferrari,668 S.E.2d
S.E.2d at
at 243; Ferrari v. Am.
Am. Home Prods. Corp.,
Corp., 650 S.E.2d 585,
585, 590
590 (Ga.
Ct. App. 2007).
2007).
82.
82. Ferrari,
Ferrari, 668
668 S.E.2d
S.E.2d at
at 238.
238.
83.
83. Id.
[d. at 239-43.
84.
84. Id
[d. at 240-43.
240--43.
85.
85. See U.S. CONST.
CONST. art. VI,
VI, cl.
cl. 2.
2.
86.
S.E.2d at
at 237
[Appellees'] design
86. See
See Ferrari,
Ferrari, 668
668 S.E.2d
237 ("[T]he
("[T]he Vaccine
Vaccine Act
Act bars
bars [Appellees']
design defect
defect claims
because
'any vaccine-related
because 'any
vaccine-related injury would
would be deemed "unavoidable"
"unavoidable" if
if the vaccine was
was properly
properly
prepared
prepared and
and accompanied
accompanied by
by proper warnings."'
warnings.'" (quoting
(quoting Ferrari
Ferrari v. Am.
Am. Home
Home Prods. Corp., 650
650
S.E.2d
S.E.2d 585,
585, 588
588 (Ga. Ct. App. 2007))).
2007»).
87.
There are
(I) Congress
Congress expressly
expressly preempts
preempts state
state
87. There
are three
three basic
basic instances
instances where
where preemption
preemption occurs:
occurs: (I)
law,
as "express
"express preemption";
preemption"; (2)
(2) Congress
Congress implements
implements a pervasive
pervasive federal
federal regulatory
regulatory scheme
scheme
law, known
known as
and
the scheme, known as
and Congress's
Congress's intent to preempt
preempt state law
law is
is inferred
inferred from the extensive
extensive nature
nature of the
"field
"field preemption";
preemption"; and (3)
(3) state
state law conflicts
conflicts with
with federal law such that
that it is either
either impossible
impossible to
to
comply
comply with
with both
both federal
federal and
and state
state law
law or
or itit would
would be
be futile
futile to
to do
do so,
so, known
known as
as "conflict
"conflict preemption."
preemption."
Sykes
2d 289,
289, 296
296 (E.D.
(E.D. Pa.
Pa. 2007).
2007).
Sykes v. Glaxo-SmithKline,
Glaxo-SmithKline, 484 F. Supp. 2d
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expressly
of
expressly preempt traditional state tort remedies with the passage of
88
88
the Vaccine Act. However, the extent
extent of the scope of the intended
intended
preemption
preemption under §§ 300aa-22(b) is unclear from89the Vaccine Act, and
courts. 89
reviewing courts.
by reviewing
interpretation by
thus requires
requires interpretation
The U.S. Supreme
specified the traditional
Supreme Court has previously specified
analysis that occurs when attempting to "identify
"identify the domain
90
expressly preempted"
preempted" by federal statutory language. 9o
Analysis of the
scope of the preemption
preemption always begins
begins with an examination
examination of the
91
91
text of the statute
statute at issue. The interpretation
interpretation of the statutory text "is
92
the nature
about
presumptions
two
by
of preemption."
preemption.,,92
informed
about the
nature of
First, it must be presumed
nonchalantly
presumed that Congress does not nonchalantly
preempt state law causes
causes of action, especially
especially in areas traditionally
traditionally
93
93
relegated
relegated to the states. As the Supreme
Supreme Court explains,
explains, "[The
"[The
analysis]
'with the assumption that the historic police powers
analysis] start[s] 'with
superseded by the Federal
of the States were not to be superseded
Federal Act unless that
94 Second, the
was the clear
Congress. ",94
clear and manifest
manifest purpose of Congress."'
purpose of Congress is paramount in understanding
understanding the scope of any
9s
95
preemption
ascertained
preemption statute. The intent of Congress is primarily ascertained
from the language
"statutory framework"
language of the statute
statute itself and the "statutory
framework"
96
it.96
surrounding
surrounding it.

88. 42 U.S.C. § 300aa-22(a)
300aa-22(a) (2006)
provided in subsections
subsections (b), (c), and (e) of this
(2006) ("Except as provided
section
section State law shall apply to a civil action brought for damages
damages for a vaccine-related
vaccine-related injury or death.")
death.")
(emphasis
(emphasis added).
added).
89. See Ferrari,
Ferrari,668 S.E.2d
S.E.2d at 238; see also Militrano
Militrano v. Lederle Labs., 769 N.Y.S.2d
N.Y.S.2d 839, 843
(N.Y. Sup. Ct. 2003).
2003).
90. Cipollone
Inc., 50S
505 U.S. 502, 517 (1992).
(1992).
Cipollone v. Liggett Group, inc.,
91. Medtronic,
of
91.
Medtronic, Inc. v. Lohr, 518 U.S. 468, 484 (1996)
(1996) (explaining
(explaining that any analysis of the scope
scope of
preemption
preemption must begin with the text at issue).
92. [d.
Id. at 485.
93. [d.
Id. (noting there is a "presumption
"presumption against pre-emption of state police power
power regulations").
regulations").
94. Id.
230 (1947)).
(1947)).
/d. (quoting
(quoting Rice v. Santa Fe Elevator
Elevator Corp., 331 U.S.
u.s. 218,
218,230
95. [d.
Id. at 485-86.
96. Id.
relevant..,
'structure and purpose of the statute as a whole,'
whole,' as revealed
[d. at 486 ("Also relevant
... is the 'structure
revealed
not only in the text, but through
reasoned understanding
through the reviewing court's reasoned
understanding of the way
way in which
Congress
and
Congress intended
intended the statute and its surrounding regulatory scheme to affect
affect business, consumers, and
the law."
law." (quoting Gade
505 U.S. 88, 98 (1992))).
(1992))).
Gade v. Nat'l Solid Wastes Mgmt. Ass'n, 50S
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B.
Traditional Preemption
Preemption Analysis to § 300aa-22(b)(1)
B. Applying the Traditional
300aa-22(b)(1)

1.
1. Textual Analysis.
Analysis: The Importance
Importance of Comment k
preemption in the Vaccine
Vaccine Act
Any consideration
consideration of the scope of preemption
must begin with an examination of the text of the preemptive
97 The preemptive
itself.97
preemptive language
statutory language
language itself.
language at issue occurs
300aa-22(b)(1), which states "[n]o vaccine
manufacturer shall be
in § 300aa-22(b)(1),
vaccine manufacturer
liable in a civil action for damages
damages arising from a vaccine-related
vaccine-related
injury or death...
if
the
injury
or
death
resulted
from
side
effects that
death ...
were unavoidable
unavoidable even though the vaccine was properly prepared and
98 Congress
was accompanied by proper directions and warnings."
wamings.,,98
Congress
300aa-22(b)(1) after comment
402A of the
modeled §§ 300aa-22(b)(1)
comment k to section 402A
99
99 Therefore, any examination of the
Restatement
(Second)
of
Torts.
Restatement (Second)
examination
00
300aa-22(b)(1) necessarily
necessarily must also explore comment k.
k.'100
text of § 300aa-22(b)(1)
Section
Section 402A provides for strict liability in product liability cases,
01
and comment k addresses products deemed "unavoidably
"unavoidably unsafe."'
unsafe.,,}OI
Comment k recognizes there are some products that are incapable
incapable of
of
completely safe for their intended use because it is
being made completely
beyond the present
present state of technology
technology or human knowledge to do
1 2
so.
0 However, these unavoidably
SO.102
unavoidably unsafe products
products are often quite
97.
97.
98.
98.
99.
100.
101.
101.
102.

Medtronic, 518 u.s.
U.S. at
at 485.
42
300aa-22(b)(l) (2006).
42 U.S.C. § 300aa-22(b)(I)
(2006).
RESTATEMENT
(SECOND) OF TORTS § 402A cmt. k
k (1965).
(1965).
REST
A TEMENT (SECOND)
Militrano
839, 844 (N.Y.
Militrano v. Lederle Labs.,
Labs., 769 N.Y.S.2d 839,844
(N.Y. Sup. Ct.
Ct. 2003).
Am. Home Prods. Corp.
Corp. v.v. Ferrari, 668
668 S.E.2d 236,239
236, 239 (Ga. 2008).
2008).
The
The full text of comment
comment kk states the
the following:
There are some
some products which, inin the present state of human knowledge, are quite
quite
incapable of being made safe
safe for
for their
their intended and
and ordinary
ordinary use.
use. These
These are
are especially
especially
common inin the
the field of drugs. An outstanding
outstanding example
example isis the vaccine
vaccine for
for the Pasteur
Pasteur
treatment of
of rabies,
rabies, which
which not
uncommonly leads
leads to
to very
very serious
damaging
treatment
not uncommonly
serious and
and damaging
consequences when it isis injected. Since
Since the disease itself
itself invariably leads to aa dreadful
death, both
both the
the marketing
use of
of the
the vaccine
vaccine are
are fully
fully justified,
notwithstanding
death,
marketing and
and the
the use
justified, notwithstanding
the unavoidable high
high degree of risk which they involve.
involve. Such aa product,
product, properly
properly
prepared, and accompanied
accompanied by
by proper
proper directions
directions and warning, is not defective,
defective, nor
nor isis it
same is true
unreasonably dangerous. The
The sarne
true of
of many
many other
other drugs,
drugs, vaccines,
vaccines, and
and the like,
many
of which
for this
this very
very reason
reason cannot
legally be
be sold
sold except
to physicians,
physicians, or
many of
which for
cannot legally
except to
or under
under
the prescription of aa physician.
physician. It isis also
also true inin particular of
of many new
new or
or experimental
drugs as
which, because
because of
of time
as to
and opportunity
for sufficient
sufficient medical
to which,
of lack
lack of
time and
opportunity for
medical
experience,
experience, there can be no assurance
assurance of
of safety,
safety, or perhaps even of purity
purity of ingredients,
ingredients,
but
as there
there is
is justifies
the marketing
use of
of the
notwithstanding
but such
such experience
experience as
justifies the
marketing and
and use
the drug
drug notwithstanding
aa medically
medically recognizable risk. The
The seller of such products, again with
with the
the qualification
qualification
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03
comment uses the vaccine for the Pasteur
useful. 1I03
The comment
Pasteur treatment of
of
104
1
0
4
rabies as an example. Despite the inherent risks in the vaccine,
vaccine, the
10 5 Thus, it is preferable
preferable to
disease itself invariably
invariably leads to death. 105
accept the risks inherent
inherent
in the vaccine
vaccine rather than the risks
06
rabies.
with
associated
rabies. 106
product
Comment k explicitly distinguishes the three basic types of product
liability claims: design defect, manufacturing
manufacturing defect, and packaging
packaging
10 7 Comment
Comment k effectively
or marketing
marketing defect. 107
effectively posits that an
unavoidably unsafe product, such as a vaccine, is not defectively
unavoidably
defectively
accompanied by adequate
designed if it is properly manufactured
manufactured and accompanied
adequate
1°8
directions. 108
warnings and directions.
300aa-22(b)(1 )-is susceptible
Unfortunately, comment k-like § 300aa-22(b)(1)-is
to ambiguous interpretation. One possibility
case-by-case
possibility is that a case-by-case
analysis is necessary to determine
whether
a
particular
determine
particular product
product is
unavoidably
unavoidably unsafe, and that it could have been made safer by an
alternative
design. 1°9 A second possibility is that all products falling
alternative design.109
within a particular
considered
particular category, such as vaccines, are considered
unavoidably
unsafe,
and
thus
strict
liability
for
design
defects is
unavoidably
llo
110
completely
At the time the Vaccine Act was adopted,
completely barred.
300aa-22(b)(1), the case law was
incorporating comment
comment k into § 300aa-22(b)(1),
divided as to which analysis was the appropriate one to apply. III
11

that
that they are properly prepared
prepared and marketed, and
and proper
proper warning
warning isis given, where
where the
the
situation calls
calls for
for it,
it, is not
not to be
be held
held to strict liability for
for unfortunate
unfortunate consequences
attending their use,
use, merely because
because he has
has undertaken to supply
supply the
the public
public with
with an
apparently useful and desirable product, attended with
with aa known
known but
but apparently reasonable
risk.
(1965).
RESTATEMENT (SECOND)
(SECOND) OF TORTS
TORTS § 402A
402A cmt.
cmt. kk (1965).
Hoffman-La Roche, Inc.,
103. Freeman
Freeman v. HotTman-La
Inc., 618
618 N.W.2d
N.W.2d 827,
827, 835
835 (Neb.
(Neb. 2000).
2000).
104. Bruesewitz
Bruesewitz v. Wyeth, Inc., 508 F.F. Supp. 2d
2d 430,
430, 445
445 (E.D. Pa.
Pa. 2007).
2007).
105. Id.
105.
Id.
106. Id.
Id.
107. Blackmon v.v. Am. Home Prods. Corp., 328
328 F. Supp. 2d 659, 664
664 (S.D. Tex.
Tex. 2004) (recognizing
(1) design
(2) manufacturing
the three basic types of product liability claims: (I)
design defect, (2)
manufacturing defect, and
and (3)
inadequate labeling or aafailure to warn).
warn).
108. Id.
Id.
N.Y.S.2d 839,
109. Militrano v.v. Lederle
Lederle Labs., 769 N'y.S.2d
839, 844
844 (N.Y.
(N.Y. Sup.
Sup. Ct.
Ct. 2003).
110.
110. Id. at
at 845.
111.
Ill. Id.
Id. at 844 (noting
(noting that
that atat the time
time the
the Vaccine Act was
was adopted,
adopted, courts had
had yet to reach
reach aa
also Freeman
consensus on the meaning
meaning of
of comment
comment kk or its application inin design
design defect litigation); see also
Freeman
Hoffran-La Roche, Inc., 618 N.w.2d
N.W.2d 827, 835 (Neb. 2000) (noting that comment k has been
v. HotTman-La
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"Blanket Immunity"
Under Comment k
a. Jurisdictions
JurisdictionsFavoring
a.
Favoring "Blanket
Immunity" Under
case-by-case determination
whether
Some jurisdictions reject a case-by-case
determination of whether
certain side effects
effects are unavoidable, instead holding that any
prescription
prescription drug is unavoidably unsafe by definition, thereby
thereby barring
112
1
12
strict liability claims for design defects. These jurisdictions argue
that unavoidably
contemplated by comment
comment k, are
unavoidably unsafe products, as contemplated
"blanket
not defectively
defectively designed as a matter of law and grant "blanket
3
immunity"
11 These courts generally justify
justify an
immunity" to their manufacturers.
manufacturers. 113
exception from strict liability
liability by focusing on the product's
product's value to
society. 114
I 14
b.
Favoringa Limited Application
Application o/Comment
of Comment k
h. Jurisdictions
Jurisdictions Favoring
Other
case-by-case analysis
Other jurisdictions,
jurisdictions, however, conclude
conclude that a case-by-case
is appropriate
appropriate to determine
determine whether a prescription
prescription drug is
115 These courts believe society's interest in
unavoidably unsafe. 115
developing prescription
adequately protected
marketing and developing
prescription drugs is adequately
protected
1 16
manufacturers.
drug
for
immunity
blanket
to
without resorting
immunity for drug manufacturers. 116
Thus, the trier of fact is responsible for determining whether, on a
case-by-case
case-by-case basis, a particular
particular product is unavoidably
unavoidably unsafe."
unsafe. I 177
Most jurisdictions following the case-by-case
case-by-case approach use a riskutility balancing analysis to determine
determine whether the benefits of a
product outweigh
outweigh its known risks."
risks. 1188 As part of this analysis, the trier
of fact must consider whether
whether there was any reasonable
reasonable alternative
alternative

interpreted
disagreement among
interpreted in a variety of ways and that there is wide-scale disagreement
among the courts concerning
its application).
112. See, e.g., Brown
Brown v. Superior Court, 751 P.2d 470, 477, 480 (Cal. 1988); Grundberg v. Upjohn
Co., 813 P.2d 89,
(Utah 1991).
1991).
89, 90 (Utah
113. Freeman,
113.
Freeman, 618 N.W.2d at 836.
836.
P.2d at 480.
114. Brown, 751 P.2dat480.
115. Am. Home Prods. Corp. v. Ferrari,
liS.
Ferrari, 668 S.E.2d 236, 239 (Ga. 2008).
116. Freeman,
Freeman, 618 N.W.2d
N.W.2d at 836 (noting
(noting that providing blanket
blanket immunity from strict liability under
under
comment
comment k is widely criticized).
criticized).
117. Id.
Id.
Hoffman-La Roche, Inc., 585 S.E.2d
723, 727 (Ga. Ct. App. 2003)
of
118. Bryant v. Hoffinan-La
S.E.2d 723,727
2003) ("[T]he
("[l1he benefits of
the product must outweigh
manufacturer
outweigh its known risks on the date the product is distributed
distributed before the manufacturer
can
liability.").
can avoid strict liability.
").
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design that would have
have accomplished
accomplished the product's
product's purpose
purpose with less
less
design
consumer.119
the consumer. I 19
risk to the

GeorgiaSupreme Court's
c. The Georgia
Court's Textual Interpretation
Interpretation of
of
§ 300aa-22(b)(1)
300aa-22(b)(l) in Light of Comment k
Ferrari, the Georgia
Georgia Supreme
Supreme Court
Court determined
determined that
that § 300aaIn Ferrari,
vaccine
against
22(b)
22(b) does not preempt
preempt all design
design defect
defect claims
vaccine
analysis with a textual
manufacturers. The court began its analysis
manufacturers.
interpretation of comment
interpretation
comment k. In examining
examining comment
comment k, the Georgia
Georgia
acknowledged the two conflicting
conflicting interpretations
interpretations
Supreme Court first acknowledged
Supreme
of comment
comment k, and determined
determined there is much disagreement
disagreement regarding
regarding
120
its application. 12o
The court
court then noted
noted that most of the states that
12 1
case-by-case basis.
the case-by-case
on the
so on
done so
have done
have adopted comment
comment kk have
basis.l2l
The court further explained
explained that other
other courts examining
examining comment
comment k in
the context of design defect litigation under the Vaccine
Vaccine Act
Act
interpretation of
erroneously
erroneously construed the comment
comment to support
support an interpretation
of
122
1
22
§ 300aa-22(b)(1)
300aa-22(b)(1) as rejecting
rejecting the case-by-case
case-by-case analysis.
For
case-by-case
example, one court held that a rejection of the case-by-case
determination of whether
determination
whether a certain side effect was unavoidable
"mirrors this
area of
of tort
law for
tort law
for unavoidably
unavoidably unsafe
"mirrors
this established
established area
1
23
pointed out that this was an
an
products.,,123 The Georgia Supreme
Supreme Court pointed
products."'
surrounding comment k was
erroneous interpretation
interpretation because the law surrounding
erroneous
of
far from established and agreed upon-and in fact, the majority
of
124
limited, case-by-case
more limited,
the more
jurisdictions
jurisdictions favor
favor the
case-by-case approach.
approach. 124
After explaining where previous courts
courts had erred in their
proceeded
comment k, the Georgia Supreme Court proceeded
interpretation
interpretation of comment
of the
in
light
300aa-22(b)(1)
with a thorough analysis of the text of §§ 300aa-22(b)(1)

Id.
119. [d.
120. Ferrari,
Fe"ari, 668 S.E.2d
S.E.2d at 239.
121. [d.
Id.
121.
Id. (stating both Sykes and Blackmon erred in their construction
122. [d.
construction of comment
comment kk and used this
this
erroneous construction to support their interpretations of the
the Vaccine
Vaccine Act).
Id.
123. [d.
(arguing that Sykes, in particular, erred
erred in its interpretation).
124. [d.
Id. at 239-40 (commenting that Bruesewitz
Broesewitz also acknowledged the Sykes court's
misunderstanding of comment k).
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125
interpretation of comment
The Court explained that the
correct interpretation
comment k. 125
conditional nature of § 300aa-22(b)(1)
300aa-22(b)(1) contemplates
contemplates situations in
avoidable, and for which the
which side effects will occur that are avoidable,
126 For
example, § 300aa-22(b)(1)
300aa-22(b)(1)
manufacturer may be liable. 126
manufacturer from civil liability
vaccine-related
insulates a manufacturer
liability if the vaccine-related
' 27
unavoidable."'
were
that
effects
side
from
"resulted
death
or
injury
side effects that were unavoidable.,,127
It certainly was within Congress's power to omit this clause, and
instead make immunity
immunity to civil litigation
litigation conditional
conditional on proper
proper
128
preparation
only. This is not how Congress
preparation and adequate warnings
warnings only.128
chose to construct the statute,
statute, however. Instead, Congress
Congress composed
composed
the statute to bar liability for side effects that are "unavoidable
"unavoidable by
by
12 9 This
packaging.,,129
means other than proper
proper manufacturing and packaging."'
if a particular
means if
particular side effect could have been
been avoided by
by
employing a feasible alternative
completely
employing
alternative design, liability
liability is not completely
30
barred. 1130

2. Legislative
History Analysis
2.
Legislative History
Following
Following its extensive analysis of the text of § 300aa-22(b)(1),
300aa-22(b)(1), the
Georgia
Supreme
Georgia
Court then examined the legislative history behind
behind
the Vaccine
Vaccine Act to ensure that its interpretation
interpretation aligned
aligned with
3 1 Although
congressional intent.
intent.'131
Although previous courts reasoned the
congressional
legislative
of
legislative history of the Vaccine Act strongly favors preemption of
all design defect claims against vaccine manufacturers,
the
Georgia
manufacturers,
Georgia
32
Supreme Court disagreed.
disagreed. 1132

U.S.C. § 300aa-22(b)(i),
125. Id.
Id. ("An analysis
analysis of
of the language and intent
intent of 42 U.s.C.
300aa-22(b)(I), unhindered by
by the
the
mistakes
mistakes of Blackmon and Sykes, shows that Congress not only
only adopted comment k, but
but understood that
comment
comment inin the
the same
same way that Bruesewitz and the
the great
great majority of other
other courts came to understand
understand
it.").
it.").
126. Ferrari,
Ferrari, 668
668 S.E.2d
S.E.2d at 240.
240.
300aa-22(b)(1) (2006).
127. 42
42 U.S.C.
U.S.C. § 300aa-22(b)(I)
(2006).
128. Ferrari,
Ferrari, 668 S.E.2d at 240.
129. Id.
Id.
Id. ("[T]he
(b)(1)
130. Id.
("[T]he last clause
clause of subsection (b)(
1) was necessary toto ensure that
that its
its bar toto liability would
not
not apply to the manufacturing
manufacturing and
and packaging process,
process, but
but only toto side effects which were
were not avoidable
by
by aa safer design.").
131. Id.
at240-42.
131.
Id. at
240-42.
See, e.g., id.
id. at
132. See,
at 240
240 (refuting the
the Georgia
Georgia Court of
of Appeals assertion
assertion that
that there isis "clear
history" supporting
legislative history"
supporting aa statutory construction that bars all design
design defect
defect claims).
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The jurisdictions
jurisdictions declaring
declaring the legislative
legislative history behind
behind the
The
Vaccine Act favors
favors aa blanket preemption
preemption analysis
analysis rely
rely on the
Vaccine
[vaccine-injured persons]
"Accordingly, if [vaccine-injured
following sentence:
sentence: "Accordingly,
following
cannot demonstrate
demonstrate under
under applicable
applicable law either
either that a vaccine
vaccine was
cannot
improperly
improperly prepared
prepared or that
that it was accompanied
accompanied by improper
improper
directions or inadequate
inadequate warnings
warnings [they] should pursue recompense
recompense
directions
133
system.,,133 These
These courts
compensation system,
system, not the tort
tort system."'
in the compensation
argue that this passage
passage clearly
clearly demonstrates
demonstrates Congress's
Congress's intent to
argue
relegate defective
defective design
design claims
claims to the
the compensation
compensation system
system
relegate
established in the
the Vaccine
Vaccine Act, rather
rather than the traditional
traditional tort
established
134
134
system. However, the Georgia Supreme
Supreme Court points
points out that the
system
compensation
Vaccine
Act
state
Committee
state
the
Vaccine
compensation
system was
did
not
Committee
1
35
mandatory.135 Rather, the system should
should be viewed as an alternative
alternative
mandatory.
136
36
traditional tort system.
particular passage in
system.' Viewing this particular
to the traditional
compensation system, the
light of the alternative nature of the compensation
meant only that "if
the
concluded
Georgia
Supreme
Court
concluded
Committee
"if
Supreme
Georgia
manufacturing
vaccine-injured person
person does not have a claim
claim for a manufacturing
a vaccine-injured
compensation system
warning defect, he should find the compensation
system appealing
appealing
or warning
even though he is authorized
authorized to attempt to prove the existence of a
37 By no means, however, does this
safer design in the tort system."'
system.,,137
passage mean that all design
defect claims against vaccine
38
1
preempted.
are
manufacturers
preempted. 138
manufacturers
Committee report upon which the
An additional
additional passage
passage from the Committee
Georgia Supreme Court relied states the following:

U.S.C.C.A.N. 6344, 6367.
reprintedin
in 1986 V.S.C.C.A.N.
REP. No. 99-908, at 26 (1986), as reprinted
133. See H.R. REp.
Bruesewitz v.
v. Wyeth,
Wyeth, Inc., 561 F.3d 233, 248 (3d 2009); Bruesewitz v. Wyeth,
134. See Bruesewitz
Wyeth, Inc., 508 F.
(E.D. Pa.
Glaxo-SmithKline, 484 F. Supp. 2d 289, 300 (E.O.
Pa. 2007);
2007); Sykes
Sykes v.
430, 442
Supp.
2d 430,
Supp. 2d
442 (E.D.
(E.O. Pa.
v. Giaxo-SmithK1ine,
Pa.
Prods. Corp.,
Corp., 328
v. Am. Home
Home Prods.
2007); Blackmon
328 F.
F. Supp. 2d 659, 664-65 (S.D.
(S.~. Tex. 2004) (stating this
2007);
Blackmon v.
clearly the
"indicates rather
passage
passage "indicates
rather clearly
the Committee's intent to relegate design defect claims to the
v. Lederle
Lederle Labs.,
Labs., 769 N.Y.S.2d
Militrano v.
system"); Militrano
compensation system");
N.Y.S.2d 839, 845 (N.Y. Sup. Ct. 2003);
compensation
(Phila. Ct.
P1. LEXIS
Aventis Pasteur, Inc., No. 3861, 2008 Phila. Ct. Com. PI.
Wright
Wright v.v. Aventis
LEXIS 221, at *31-32 (phila.
Com. P1.
PI. Aug.
Aug. 27,
27, 2008).
2008).
Com.
135. Ferrari,
Ferrari, 668 S.E.2d at 242-43 (noting the legislative history does not indicate that use of the
alternative compensation system is required).
required).
U.S.C.C.A.N. 6344, 6367
as reprinted
reprintedin
in 1986 V.S.C.C.A.N.
REP. No. 99-908, at
136. H.R. REp.
at 26, as
6367 (stating potential
tort plaintiffs "now have an appealing alternative to the tort
tort system").
668 S.E.2d
S.E.2d at
at 241.
241.
137. Ferrari,
Ferrari, 668
Id.
138. Id.
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The Committee has set forth Comment
Comment [k] in this bill
because it intends that the principle in Comment [k]
"unavoidably unsafe" products, i.e. those
regarding "unavoidably
products which in the present state of human
human skill and
cannot
be
made
safe,
apply
to the vaccines
knowledge
products
covered
covered in the bill and that such
products not be the subject
39
system.'
tort
the
system. 139
of liability in
Ironically, other courts rely on this exact passage
passage to support
support the
position that the Vaccine
Vaccine Act does preempt all defective design
14
claims. 140
This passage
passage appears to be susceptible to two different
different
14 2
14 1 On the one hand, it clearly adopts comment k.
interpretations. 141
it clearly adopts comment k.142
interpretations.
Such an adoption is subject to an interpretation
interpretation that the majority view
of comment
comment k applies, meaning vaccines should be examined
examined on a
case-by-case
case-by-case basis to determine
determine whether they are unavoidably
unavoidably
143
interpretation advocated by the Georgia
Georgia
unsafe. 143 This is the interpretation
l44
144
Supreme Court.
COurt. On the other hand, the passage
passage clearly exempts
"unavoidably
vaccines
vaccines from tort liability if they are deemed "unavoidably
145
unsafe."'
unsafe." 145 As this passage
passage demonstrates,
demonstrates, so much of the
interpretation of the legislative history behind the Vaccine Act is
interpretation

139. H.R. REp.
REP. No. 99-908,
U.S.C.C.A.N. 6344, 6367.
139.
99-908, at 26, as reprintedin
reprinted in 1986 U.S.C.C.A.N.
140.
140. See Sykes
Sykes v. Glaxo-SmithKline,
Glaxo-SmithKline, 484 F. Supp. 2d 289, 300 (E.D. Pa. 2007); Blackmon
Blackmon v. Am.
Am.
(S.D. Tex. 2004); Militrano v. Lederle Labs., 769
Home Prods. Corp., 328 F. Supp. 2d 659, 664-65 (S.D.
N.Y.S.2d 839,
N.Y.S.2d
839, 845-46 (N.Y. Sup. Ct. 2003).
2003).
141.
141. The interpretation
interpretation advocated by the Georgia
Georgia Supreme Court argues that this passage "bolsters"
"bolsters" a
design defect
defect claims. Ferrari, 668 S.E.2d at
construction of the Vaccine Act that does not preempt all design
other hand, the United States District Court for the Southern
Southern District of Texas claims
claims the
242. On the other
Blackmaon, 328
passage suggests Congress intended
intended that the Vaccine Act absorb
absorb all design defect
defect claims. Blackmon,
F. Supp. 2d at 664-65.
664-65.
in 1986 U.S.C.C.A.N.
142.
No.99-908, at 26, as reprinted in
REp. No.
U.S.C.C.A.N. 6344, 6367.
142. H.R. REP.
N.Y.S.2d at 845 (arguing Congress is presumed to have known of the debate
143. See Militrano, 769 N.Y.S.2d
surrounding
Vaccine Act).
surrounding comment
comment k when it was adopted in the Vaccine
Ferrari, 668 S.E.2d
144. Fmari,
S.E.2d at 242. But see Militrano v. Lederle Labs., 810 N.Y.S.2d
N.Y.S.2d 506, 508 (N.Y.
(N.Y.
2006) ("While the initial
App. Div. 2006)
initial language in the House Committee
Committee Report
Report with respect to Comment k
...
... appears to leave
leave open
open the possibility of a design defect
defect claim with
with respect to vaccines
vaccines covered by the
Vaccine
House Committee's discussion
discussion of the issue clearly establishes
Vaccine Act, the balance
balance of the House
....
").
Congress'[s]
determination that the Comment k defense
defense bars all such claims
claims ....
").
Congress'[s) determination
99-908, at 26, as reprinted in 1986 U.S.C.C.A.N.
6344,6367.
REp. No.
No. 99-908,
U.S.C.C.A.N. 6344,
6367.
145. H.R. REP.
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and the
dependent upon
upon which
which explanation
explanation of
of comment
comment k is accepted,
accepted, 46
the
dependent
1
preferred.
it
which
identify
clearly
Committee report does not clearly identify which it preferred. 146
Committee
exploring the 1986
1986 Committee
Committee report
report on the Vaccine
Vaccine
In addition to exploring
Court
Supreme
intent, the Georgia
Georgia Supreme Court also
also
congressional intent,
Act to decipher congressional
examined subsequent
subsequent legislative
legislative history in an attempt
attempt to glean
glean
examined
147
Recognizing
additional evidence
evidence of the purpose
purpose behind the Act.
ACt,147
Recognizing
additional
same committee
committee that originally
originally considered
considered the
the Vaccine
Vaccine
that the exact same
subsequent
produced the 1986 report also produced
produced a subsequent report
report
Act and produced
Georgia Supreme
Supreme Court
Court examined
examined this
this report
report "to
"to 'shed[
'shed[ ]
]
in 1987,
1987, the Georgia
148
ambiguous language'" in
in the Vaccine
Vaccine Act.
ACt,148 The
The
light on allegedly ambiguous
1987 report
report states unequivocally
unequivocally that "the
"the codification
codification of Comment
Comment
not
intended
was
of
Torts
Restatement (Second)
(Second)
intended to decide
(k) of the Restatement
as a matter of law the circumstances
circumstances in which
which a vaccine
vaccine should be
be
49
deemed unavoidably
unavoidably unsafe.'
unsafe.,,149 Instead, such determinations
determinations should
should
' 50
law."'
"applicable
with
accordance
in
made
be
be left to courts, to
accordance with "applicable law.,,150
Court's
This statement appears to support the Georgia Supreme
Supreme Court's
300aa-22(b)(1) does not bar all design defect claims
assertion that § 300aa-22(b)(1)
law.151
of
matter oflaw. 151
as a matter
rejected
Additionally, the Georgia Supreme Court pointed to a rejected
the
1987
in
amendment
to
the
Vaccine
Act
that
was
discussed
1987
amendment
interpretation that Congress
Committee report to further support its interpretation
Committee
152
claims. 152
defect claims.
on design
bar
automatic
bar on
design defect
did not intend to impose an
The Court noted that an amendment
amendment that would have stated that
"failure to develop [a] safer vaccine was not grounds for liability was
consideration of the
rejected by the Committee
Committee during its original
original consideration

the principle
principle in
intended that the
Committee intended
the Committee
146. [d.
in comment k regarding unavoidably
Id. (stating
(stating the
unsafe products apply to vaccines, but neglecting to mention which of the two competing interpretations
unsafe
interpretations
should apply).
of
apply).
of comment
comment k should
Ferrari,668
147. Ferrari,
147.
668 S.E.2d at 241.
CI. 324,
148.
States, 71
71 Fed.
Fed. CI.
324, 335
335 (2006)).
v. United
United States,
Imps. v.
Grapevine Imps.
Id.(quoting
(quoting Grapevine
148. [d.
as reprinted
reprinted in 1987 U.S.C.C.A.N.
(1987), as
No. 100-391(1),
100-391(), at 691 (1987),
REP. No.
149.
U.S.C.C.A.N.
Id.(referencing
(referencing H.R. REp.
149. [d.
2313-365).
2313-1, 2313-365).
2313-1,
Id.
150. [d.
the Georgia
Georgia Supreme Court appears
by the
referenced by
151.
The statement
statement referenced
appears to expressly
expressly reserve aa position
151. The
a statement
statement would
Such a
unsafe. Such
for
in determining
whether vaccines
unavoidably unsafe.
would support
vaccines are unavoidably
determining whether
the courts
courts in
for the
Id.
not preempted by federal law. [d.
defect claims
claims are not
all design
design defect
theory that
that all
the
Court's theory
Supreme Court's
the Georgia
Georgia Supreme
Id.
152. [d.
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[Vaccine] ACt.,,153
proposed amendment,
Act."' 5 3 From the rejection of this proposed
the Court infers that Congress did not intend "to include the
provisions embodied in the rejected amendment.,,154
amendment."' 154 Thus, Congress
did not intend to grant blanket immunity to manufacturers
manufacturers for design
1 55
interpretation of the meaning
plausible interpretation
meaning of the
defects. 155 This is a plausible
interpretation is that
rejected amendment. However, another plausible
plausible interpretation
Congress
manufacturers accountable
accountable for failing
Congress did not want to hold manufacturers
to find safer alternatives to their products as currently
currently designed, not
necessarily that they are liable for design defect claims.
After extensively examining
300aa-22(b)(1), and
examining the text of § 300aa-22(b)(1),
and
attempting
congressional intent behind this statutory
attempting to determine the congressional
legislative history, the Georgia Supreme
provision from the relevant legislative
"clearly does not preempt
Court held the Vaccine Act "clearly
preempt all design
defect claims against vaccine
vaccine manufacturers,
manufacturers, but rather provides that
such a manufacturer
manufacturer cannot be held liable for defective design if it is
case-by-case basis, that the particular vaccine
determined, on a case-by-case
vaccine was
' 1 56
unavoidably
"would
unsafe.,,156 Granting such widespread
widespread immunity
immunity "would
unavoidably unsafe.'
'have
immunity from
'have the perverse effect of granting complete
complete [tort] immunity
'
157
industry."",157 This conclusion is
design defect liability to an entire industry.
legislative history behind the Vaccine
supported by the legislative
Vaccine Act.
Unfortunately, an opposite conclusion can also be garnered from the
58 These contradictory conclusions
Act. 1158
These contradictory conclusions
legislative history
history behind the ACt.
are the result of Congress's reliance on comment
comment k in fashioning the
preemptive
300aa-22(b)(1). Because
Because comment k itself
itself
preemptive language of § 300aa-22(b)(I).
susceptible to differing interpretations,
interpretations, and Congress does not
is susceptible
expressly state which interpretation
interpretation it favored, it is unlikely the
expressly
Ferrari,668 S.E.2d at
100-391(f), at 691,
691, as reprinted
153. Ferrari,
at 241
241 (quoting H.R. REP.
REp. NO.
No. 100-391(1),
reprinted in 1987
1987
U.S.C.C.A.N. 2313-1,
2313-1, 2313-365).
2313-365).
Id.(quoting
SHAMBLE SINGER,
AND
154. Id.
(quoting NORMAN
NORMAN J. SINGER && J.D. SHAMBlE
SINGER, 2A
2A SUTHERLAND
SUTHERLAND STATUTES AND
STATUTORY CONSTRUCTION §§ 48:18
(7th ed.
ed. 2008)).
STATUTORYCONSTRUCfION
48:18 (7th
2008».
155. Id.
Id.at
at242.
ISS.
242.
Id.
156. Id.
Id. at 243 (quoting Doyle
157. Id.
Doyle v. Volkswagenwerk
Volkswagenwerk Aktiengesellschaf,
Aktiengesellschaft, 481
481 S.E.2d 518,
518, 521 (Ga.
1997)).
1997».
158. Courts other than the Georgia
Georgia Supreme
Supreme Court
Court have examined the legislative history
history behind
behind the
Vaccine
Vaccine Act and have reached aa different conclusion.
conclusion. E.g., Bruesewitz v.v. Wyeth,
Wyeth, Inc., 508 F.
F. Supp. 2d
2d
Pa. 2007);
430, 442 (E.D. Pa.
Pa. 2007);
2007); Sykes
Sykes v. Glaxo-SmithKline, 484 F. Supp. 2d 289,
289, 300
300 (E.D. Pa.
2007);
Blackmon v. Am. Home Prods. Corp., 328 F. Supp.
Supp. 2d
2d 659, 664
664 (S.D. Tex.
Tex. 2004);
2004); Militrano
Militrano v.v. Lederle
Labs.,
Labs., 769 N.Y.S.2d 839, 845 (N.Y. Sup. Ct. 2003).
2003).
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debate on the scope of the Vaccine Act's preemption
preemption of design defect
defect
59
Court.'
Supreme
U.S.
the
by
intervention
claims will end without intervention by the U.S. Supreme Court. 159
GRANTING "EXCEPTIONAL
III. PROPOSAL:
PROPOSAL: GRANTING
"EXCEPTIONAL PRODUCT"
PRODUCT" STATUS TO

NECESSARY CHILDHOOD VACCINES

Products Corp.
Corp. v. Ferrari
The decision in American Home Products
Ferrari has
upset the uniformity of vaccine design defect litigation in the United
United
States, and requires
requires resolution to ensure that the Vaccine Act is
applied fairly and consistently throughout the states. To ensure
vaccine
vaccine manufacturers
manufacturers are not subject to differing standards
standards in
various states, vaccines
products" of
of
vaccines should be deemed "exceptional
"exceptional products"
significance, and granted limited
immunity from design
great social significance,
limited immunity
defect suits. Such a designation is compatible
compatible with Congress's
Congress's
purposes
purposes in enacting
enacting the Vaccine Act and would help protect
protect the
nation's supply of childhood
childhood vaccines.
A. The Ramifications
Ramifications of Ferrari-A
Ferrari-ALoss of Uniformity
Uniformity
The Georgia Supreme
Supreme Court's decision in American Home
Products
Corp. v. Ferrari
Ferrarithreatens
threatens to have far reaching
reaching ramifications
ramifications
Products Corp.
suffering vaccinefor vaccine
vaccine manufacturers, potential tort plaintiffs
plaintiffs suffering
vaccine160
Since
Since the
related injuries, and the American
American public as a whole.
manufacturers have remained
enactment of the Vaccine
Vaccine Act, vaccine
vaccine manufacturers
161
The Georgia
Georgia
relatively sheltered from design defect litigation. 161
Vaccine Act has renewed
renewed the
Supreme Court's interpretation
interpretation of the Vaccine

159. The Georgia Supreme Court appears to suggest
"we
159.
suggest this at the close
close of its opinion, stating that ''we
300aa-22 (b)(1),
must reject such a far-reaching interpretation of 42 U.S.C. § 300aa-22
(b)(I), at least until the Supreme
issue." Ferrari,
Ferrari, 668 S.E.2d
S.E.2d at 243.
243.
Court of the United States has spoken on the issue."
160. Yi,
supra note
note 79
79 ("If even one state
160.
Vi, supra
state ..... . opens its courts to civil
civil suits against vaccine
vaccine
manufacturers, [the] carefully crafted
[established by the Vaccine Act] would be
manufacturers,
crafted federal system [established
disrupted.").
161. See Sloan et aI.,
al., supra
(explaining that the National Childhood
Childhood Vaccine
Vaccine Injury
161.
supra note 9, at 2444 (explaining
Injury
also Paul
Act of 1986 protected
protected vaccine manufacturers
manufacturers from litigation until relatively recently);
recently); see also
Vaccines, Immune 10
to Reason,
Reason, WASH.
WASH. POST, THINK TANK
TowN, Oct. 12, 2007,
Howard, On Vaccines.
TANK TOWN,
http://www.washingtonpost.com/wp-dyn/contentarticle/2007/10/1
1/AR2007101
101597.html.
http://www.washingtonpost.comlwp-dynlcontentlarticleI2007
/10/11/
AR20071 0 1101597
.htrnl.
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162 An increase
increase in vaccine
vaccine
industry's concerns about liability. 162
conditions that led
led
litigation will likely result in a repeat of the conditions
Vaccine Act in the first place-more
Congress to adopt the Vaccine
manufacturers may elect to leave the market, resulting in higher
manufacturers
higher
163
163
vaccines.
critical
and
necessary
of
prices and shortages
shortages necessary and critical vaccines.
The fear of vaccine
vaccine shortages
shortages is well founded. With only five
companies
companies producing all of the routine vaccines for the Unites States,
the country has experienced shortages several times in recent
recent
164
164
years. The profit margin on vaccine
vaccine development and production is
relatively
relatively low. 165 Manufacturers
Manufacturers cannot justify production
production of vaccines
vaccines
166
if they fail to bring in profits. 166
The increase
increase in litigation that will
Ferrari decision will inflate operating costs for
likely result from the Ferrari
manufacturers,
manufacturers, further decreasing
decreasing profit margins.
As the Georgia Supreme
Supreme Court itself contemplated,
contemplated, it is highly
highly
likely the United States Supreme Court will be required to determine
determine
167
preemptive language
300aa-22(b).).167
the scope of the preemptive
language in § 300aa-22(b
With the
Vaccine Act, Congress
Congress created a single statutory
enactment of the Vaccine
68 As the litigation
framework, applicable
litigation landscape now
now
applicable nationwide.
nationwide.1168
stands, the Georgia Supreme Court's decision upsets the uniformity
uniformity

162.
Associated Press, Couple Can Sue Vaccine Company,
Company, Court
Lawsuit Claims
162. Associated
Court Says: Lawsuit
Claims Mercury
Mercury
Preservative
Responsible for Child's
Child's Autism, MSNBC.CoM,
MSNBC.COM, Oct. 7, 2008,
Preservative in Shot Responsible
http://www.msnbc.msn.com/id/27065692/ [hereinafter Couple
Couple Can
Can Sue].
http://www.msnbc.msn.comlidl27065692/[hereinafter
163.
supra note 9,
163. See Sloan et al.,
aI., supra
9, at 2444 (noting that a surge of lawsuits in the 1980s led to
concerns
concerns about the supply of childhood vaccines,
vaccines, and the recent surge
surge in thimerosal litigation has
renewed the industry's concerns about
about liability).
id. at 2443 (noting that in 2001-2002,
2001-2002, the United States experienced
164. See id
experienced shortages
shortages in the supply
supply
of eight of the eleven recommended
childhood vaccines); see also
also Arthur E. Foulkes &
recommended childhood
& Nicolas
Nicolas Heidon,
Vaccine Shortage
Shortage Leads to the FDA's
FDA's Doorstep,
Doorstep, INVESTOR'S
Vaccine
INVESTOR'S BuS. DAILY, Oct. 22,
22, 2004, available
available at
http://www.independent.org/newsroom/article.asp?id=1374
shortages
http://www.independent.orglnewsroomlarticle.asp?id=1374 (explaining
(explaining that severe
severe vaccine shortages
from 2000 to 2003 forced forty-nine states to implement rationing
rationing for common, yet critical,
critical, vaccines).
165. For an overview of the many factors that contribute to the low financial returns on vaccine
vaccine
development
supra note 9, at 2443-44. The article outlines the costly
development and production,
production, see Sloan et al.,
aI., supra
costly
process associated with developing
developing a new vaccine, describes the stringent
stringent FDA regulations
regulations relating to
production, and explains how litigation expenses contribute to make vaccines
vaccines high-risk, low return
return
investments
manufacturers. Id.
investments for manufacturers.
Id
166. See id
id. at 2444.
Ferrari, 668 S.E.2d 236, 243 (Ga. 2008).
167. Am. Home Prods. Corp. v. Ferrari,
168. Sykes v. Glaxo-SmithKline,
Glaxo-SmithKline, 484 F. Supp. 2d 289, 301 (E.D. Pa. 2007) (.'Congress
("'Congress [did not]
168.
leave vaccine design standards
standards open to reexamination under the laws of each state, with the potential
potential for
.... "'
'" (quoting Ferrari v. Am.
interstate conflict: the Vaccine Act sets one rule, applicable
applicable nationwide ....
02-VS-031404-F, slip op. at 10 (State Ct. of Fulton County, Ga., Nov. 30,
Home Prods. Corp., No. 02-VS-031404-F,
2005))).
2005»).
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of how the Vaccine Act has previously been interpreted
interpreted in federal
169
conflict exposes vaccine
and state courts. 169 Such interstate conflict
170
regimes. 170
tort
inconsistent
manufacturers
manufacturers to potentially inconsistent tort regimes.
The opinions of both the Georgia Supreme Court and the federal
and state courts that have previously
of
previously ruled on the preemptive
preemptive effect of
the Vaccine
Vaccine Act are well reasoned and point to ample
ample legislative
history to support their decisions-and
decisions-and yet they come to opposite
conclusions.
divergence is due to the two conflicting
conclusions. This divergence
conflicting
interpretations of § 300aa-22(b)
300aa-22(b) of the Vaccine
Act:
the
interpretation
Vaccine
interpretation
favored by the Georgia
Georgia Supreme Court requires a determination,
determination, on a
case-by-case basis, of whether the adverse side effects
effects from a
case-by-case
particular vaccine are unavoidable,171
particular
unavoidable,171 and the interpretation
interpretation advanced
advanced
by other state and federal courts posits that vaccine
vaccine injuries are
unavoidable
unavoidable and subject
subject to preemption
preemption so long as the vaccine was
properly prepared
prepared and accompanied
accompanied by proper directions and
and
warnings. 172 As has been demonstrated, these differing interpretations
are the result of the disagreement
disagreement regarding the application
application of
of
17 3 Thus,
300aa-22(b).).173
comment k, which was expressly adopted by § 300aa-22(b
any resolution of whether the Vaccine
Vaccine Act preempts design defect
claims must not only look to Congress's
Congress's primary
primary objectives
objectives in
enacting the Vaccine
Act-to
ensure
the
stability
of
the
childhood
stability
childhood
Vaccine Act-to
vaccine
compensating the claims of vaccinevaccine market, while also compensating
manner-but also to the underlying
underlying
injured children in a predictable
predictable manner-but
meaning
comment k.
meaning of comment

169. Couple Can Sue, supra note 162.
162.
170. See Brief
Brief for
for Pacific
Pacific Legal
Legal Foundation
Foundation as Amicus
Petitioners at
at 16,
16, Am.
Am.
Amicus Curiae
Curiae Supporting
Supporting Petitioners
Home Prods. Corp. v. Ferrari,
Ferrari, 129 S.S. Ct. 2786 (Apr. 7,7, 2009)
2009) (No.
(No. 08-1120) ("Absent federal
preemption against
the possibility
of state
tort claims,
claims, pharmaceutical
pharmaceutical companies
companies operating
operating nationwide
nationwide
preemption
against the
possibility of
state tort
are subject to differing legal standards because
because courts
courts throughout
throughout the
the fifty states
states may
may answer
answer the same
same
liability questions
questions differently
differently....").
liability
....").
171.
171. Ferrari,
Ferrari, 668
668 S.E.2d at 242.
at239.
172. Id.
Id. at
239.
173.
173. Id.
/d. at 239-40;
239-40; see also Militrano v. Lederle Labs., 769
769 N.Y.S.2d 839, 844-45 (N.Y.
(N.Y. Sup. Ct.
2003).
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"ExceptionalProducts
Doctrine
B. The "Exceptional
Products"" Doctrine
The Eighth Circuit has put forth a persuasive analysis of comment
comment
k's application in products
products liability
liability cases
cases that may, at least in part,
74
resolve the dilemma.
dilemma.'174 The court's analysis first notes that the policy
policy
behind comment k acknowledges
that
some
unreasonably
acknowledges
unreasonably dangerous
of
products benefit society to such an extent that placing the risk of
injury on the consumer, rather than the manufacturer, is justified, so
long as the product is properly
properly manufactured and accompanied
accompanied by
by
175
75
adequate
adequate warnings.'
warnings. However, the court goes on to explain that the
"exceptional products"
language of comment k suggests that only "exceptional
products"
1
76
liability.
Specifically, comment k
should be exempt from strict liability.176
uses the vaccine for the Pasteur treatment
treatment of rabies as an example to
imply that only products
with
exceptional social need fall within the
products
exceptional
177
The Eight Circuit concludes its theory by
comment's exception. l77
surmising that the "unavoidably
"unavoidably unsafe exception
exception
should apply only
only
178
need.'
social
exceptional
upon a showing of exceptional social need.,,178
C. Applying the "Exceptional
"ExceptionalProducts
C.
Products"" Doctrine
Doctrine to Vaccines
Such an application
application of comment
comment k could
could easily be applied
applied to
of
vaccines, and doing so would ensure that the two ultimate goals of
300aa-22(b) of the Vaccine
Congress in enacting
enacting § 300aa-22(b)
Vaccine Act are still met.
It is undisputed that vaccines can cause severe side effects in some
179 Yet vaccines are also enormously important
individuals. 179
important to the

174. LITIGATING
CASES § 60:27
(Roxanne Barton
Gregory S.
S. Cusimano
Cusimano eds.,
eds., 2008).
174.
LITIGATING TORT
TORT CASES
60:Z7 (Roxanne
Barton Conlin
Conlin & Gregory
Z008).
175.
F.2d 1064, 1068--69
1068-69 (8th
175. Hill v. Searle Labs., 884
884 F.Zd
(8th Cir. 1989). Note
Note that
that comment kk itself
itself only
addresses liability
premised on
of strict
strict liability.
liability. RESTATEMENT
(SECOND) OF
OF TORTS
TORTS § 40ZA
402A
addresses
liability premised
on aa theory
theory of
RESTATEMENT (SECOND)
cmt. kk (1965).
(1965). Courts, however, have
have unanimously agreed
agreed that
that Congress's
Congress's adoption
adoption of the comment
comment in
300aa-22(b) is applicable to liability premised
See, e.g.,
§ 300aa-ZZ(b)
premised on
on both
both strict
strict liability and
and negligence. See,
e.g., Sykes
v.
v. Glaxo-SmithKline,
Glaxo-SmithKline, 484
484 F.F. Supp. 2d
Zd 289,
Z89, 303
303 (E.D. Pa. 2007).
Z007).
Hill, 884
F.2d at 1069.
176. Hill,
884 F.Zd
Id. ("[T]he
given-the vaccine
rabies-suggests that
177. Id.
("[T]he example given--the
vaccine for
for the
the Pasteur treatment
treatment of
of rabies-suggests
that only
only
special products,
with exceptional
exceptional social
social need,
fall within
within the
the gamut
gamut of
of comment
those with
special
products, those
need, fall
comment k.").
k.").
178. The
The Court
Court then added that aa showing of exceptional social need "should be
be determined on
on aacaseby-case
basis." Id.
by-case basis."
Id. The solution
solution proposed
proposed inin this paper,
paper, however, suggests that
that aa showing of
of exceptional
social need does not
not have
have to be determined
determined on
on aa case-by-case
case-by-case basis in the
the courts, but
but can also be
determined
congressional action,
action, such
such as
as the
Vaccine Act.
determined via
via congressional
the Vaccine
REP, No. 99-908, at
as reprinted
reprintedin 1986
179. H.R. REp.
at 66(1986),
(1986), as
1986 U.S.C.C.A.N. 6344, 6346-47.
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well-being
whole.'180 Just as comment
comment k recognizes
well-being of society
society as a whole.
recognizes the
need for the Pasteur treatment of rabies, despite its potential for lethal
side effects, "The Vaccine
Vaccine Act reflects a congressional
determination
congressional determination
that the disappearance
childhood vaccines
vaccines would
disappearance or unavailability
unavailability of childhood
cause
cause far greater harm than the inevitable
inevitable but limited injuries caused
caused
181
by the vaccines themselves.,,181
themselves." Given the exceptional
exceptional need of society
for the availability of affordable childhood vaccines, it would be
reasonable
"unavoidably unsafe"
unsafe" exception
reasonable to apply the "unavoidably
exception to the routine
childhood vaccines covered in the Vaccine
Vaccine Act and deem these
particular
"exceptional products"
products" that are shielded from
particular vaccines
vaccines "exceptional
from
182 Furthermore,
design defect suits by statute. 182
the
scope
of
the
Furthermore,
exemption from litigation could be limited to only those side effects
recognized in the Vaccine Act's "Vaccine
"Vaccine Injury Table,"
Table," thereby
thereby
recognized
manufacturers only receive immunity from suit in
ensuring that manufacturers
instances where
determined there is an important social
where Congress has determined
need.
300aa-22(b) of the Vaccine Act
This application
application of comment k to § 300aa-22(b)
is consistent
consistent with Congress's
Congress's ultimate concerns in enacting
enacting the
comprehensive
statute.
It
is
reasonable
to
infer
Congress
intended an
comprehensive
reasonable
interpretation of the Vaccine Act that protects manufacturers
manufacturers from
interpretation
design defect suits because doing so would encourage more
manufacturers to remain in the market. 183
183 As one court noted,
[T]he
[T]he Vaccine
Vaccine Act's purpose of protecting vaccine
manufacturers from the unpredictability
unpredictability and expense
manufacturers
expense of the tort
system would be thwarted by allowing juries
juries to decide on a casecaseby-case
basis
whether
a
vaccine
was unavoidably
by-case
unavoidably unsafe because
subjected to the
"[t]he manufacturers would again be subjected
180. Id
reprintedin 1986
1986 U.S.C.C.A.N.
Id. at
at 5-6,
5--6, as reprinted
U.S.C.C.A.N. 6344,6345-46.
6344,6345-46.
181.
181. Blackmon v.v. Am.
Am. Home
Home Prods.
Prods. Corp., 328 F. Supp. 2d
2d 659,
659, 663 (S.D. Tex. 2004).
2004).
182. For
For example,
v. Searle
product at
at issue was an intrauterine
182.
example, inin Hill
Hill v.
Searle Laboratories,
Laboratories, the
the product
intrauterine
contraceptive device (an IUD).
IWD). 884
Cit. 1989). The
contraceptive
884 F.2d 1064, 1065 (8th Cir.
The court determined
determined the
the product
product
"exceptional product"
birth control
control were
were available
available
did not qualify as
as an "exceptional
product" because alternative
altemative methods of birth
and there was
was no showing that
that IUDs inin general were exceptionally beneficial to society. Id.
Id. at 1069-70.
Congress has
has determined,
determined, on
on the other
other hand,
hand, that vaccines
vaccines are vitally important to America's
America's public
public
H.R. REP.
as reprinted
reprintedin 1986 U.S.C.C.A.N. 6344, 6346.
health. HR
REp. No.
No. 99-908, at 5, as
183.
Blackmon, 328
328 F.
Supp. 2d
665; Sykes
Sykes v.
v. Glaxo-SmithKline,
Supp. 2d
302
183. See Blackmon,
F. Supp.
2d atat 665;
Glaxo-SmithKline, 484
484 F.F. Supp.
2d 289,
289, 302
(E.D. Pa. 2007).
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unpredictability and expense
unpredictability
expense of the tort system and companies
companies
would be dissuaded from remaining
remaining or entering
entering the vaccine
84
market."
market."'1184
Allowing case-by-case
case-by-case inquiries by juries would not protect vaccine
vaccine
85 Yet
manufacturers from expensive and unpredictable
litigation.'185
manufacturers
unpredictable litigation.
Congress clearly stated this was one of the primary goals addressed
addressed
1
86
by the Vaccine
Vaccine Act. 186 Thus, to ensure Congress's goal of
of
encouraging
manufacturers
to
enter
or
remain
in
the
vaccine
market
encouraging manufacturers
vaccine
is met, the only reasonable
reasonable interpretation of § 300aa-22(b)
300aa-22(b) is that it
187 An
absolutely
AM
absolutely protects manufacturers
manufacturers from design defect claims. 187
approach
approach allowing
allowing a case-by-case
case-by-case inquiry "would
"would defeat the
protection the Vaccine Act was intended
to
provide
to the vaccine
intended
vaccine
1 88
vaccines."
childhood
of
supply of childhood vaccines.,,188
the supply
manufacturers
manufacturers and, in turn, to the
Additionally, the classification
classification of childhood vaccines
vaccines as
"exceptional
products"
shielded
from
design
defect
"exceptional products" shielded from
liability for a
limited set of side effects that are deemed "unavoidable"
"unavoidable" is
compatible
compatible with Congress's
Congress's second goal of ensuring reliable and
timely compensation
compensation for those injured by vaccines. In granting
granting
manufacturers
manufacturers limited liability from design defect suits for
"unavoidable" side
side effects
"unavoidable"
effects under
under §
§ 300aa-22(b),
300aa-22(b), Congress did not
189 Rather, the
eliminate compensation for vaccine-injured
vaccine-injured children. 189
Vaccine
compensation through an alternative to the
Vaccine Act provides
provides for compensation
system-an alternative
traditional tort system-an
alternative that is designed to be
190 Moreover, the injured
consistent, predictable,
predictable, and timely. 190
individual need not prove causation
causation or fault, and alleged
alleged defective
184.
Pl. LEXIS 221,
184. Wright v. Aventis Pasteur,
Pasteur, Inc., No. 3861,
3861, 2008
2008 Phila. Ct. Com. PI.
221, atat *23 (Phila.
Pl. Aug.
Ct. Com.
Com. PI.
Aug. 27, 2008)
2008) (quoting
(quoting Sykes, 484
484 F.F. Supp. 2d
2d at 301-02).
2007).
185. Bruesewitz v. Wyeth,
Wyeth, Inc., 508
508 F.F. Supp. 2d
2d 430,445
430, 445 (E.D. Pa.
Pa.2007).
186.
as reprinted
reprintedin 1986 U.S.C.C.A.N. 6344,6347-48.
6344, 6347-48.
186. H.R. REP.
REp. No. 99-908,
99-908, atat 6-7, as
187.
187. Sykes, 484 F.
F. Supp. 2d
2d atat 301-02 ("[T]he
("[T]he purpose
purpose of the Vaccine Act would not be
be served ifif
defective design
design claims
claims could be tried
tried before
before juries.").
188.
Pl. LEXIS
LEX1S 221,
221, at *31.
*31.
188. Wright, 2008 Phila. Ct. Com. PI.
§§ 300aa-l0
300aa-10 to -34
189. Id.
!d. at *23; see also
also 42
42 U.S.C. §§
-34 (2006).
190. Sykes, 484 F.
F. Supp. 2d
2d atat 297; see also Brief for the
the United
United States
States as Amicus
Amicus Curiae at 4,4, Am.
Home Prods. Corp. v. Ferrari, 129 S.S. Ct.
Ct. 2786 (Jan. 29, 2010) (No.
(No. 08-1120) (noting the Court
Court of
of
compensation to
Federal Claims
Claims awards compensation
to approximately
approximately one-third of
of all claimants,
claimants, and that
that the
the average
award exceeds $750,000).
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design
design claims are compensated
compensated under this alternative no-fault
191
Classifying childhood
childhood vaccines
vaccines as "exceptional
system. 191 Classifying
"exceptional products"
and limiting those who suffer vaccine-related
vaccine-related injuries
injuries to the
alternative
no-fault
system
for
design
defect
claims
strikes
alternative
a balance
between
congressional objectives of the Vaccine Act:
between the two congressional
compensating
protecting
compensating injured individuals and
protecting vaccine
92
liability.'
tort
excessive
from
manufacturers
manufacturers
excessive tort liability. 192
An application
application of comment k to §§ 300aa-22(b)
300aa-22(b) of the Vaccine
Vaccine Act
that grants routine childhood vaccines status as legislativelydetermined
"exceptional products"
determined "exceptional
products" and limits design defect claims
against the manufacturers of these vaccines
vaccines for side effects that the
Vaccine Act deems "unavoidable"
necessary to ensure the Act's
Act's
"unavoidable" is necessary
efficacy. This interpretation does not necessarily protect
manufacturers
manufacturers from all design
design defect suits, but from suits that are
premised
premised on liability
liability for side effects that have been deemed
"unavoidable"
the Vaccine
Vaccine Act.
Act. 193
"unavoidable" by
by the
193 If a particular vaccine
vaccine is
covered by the Vaccine Act, and the alleged harmful side effect is
listed in the Vaccine
Vaccine Injury Table, the manufacturer
manufacturer would be
protected
protected from a design defect suit. A case-by-case
case-by-case inquiry would be
prohibited. Alternatively, if a vaccine
is
vaccine not covered by the Act, or if
if
a vaccine is covered under the Act but the alleged harmful side effect
effect
suffered by the plaintiff is not listed in the Vaccine Injury Table, the
plaintiff is not barred from filing a design defect suit against the
194 This interpretation ensures
vaccine
that the federal
vaccine manufacturer. 194
government's efforts
efforts to establish
establish a uniform national standard
standard for
for
195
195
childhood vaccines
vaccines under
under the Vaccine Act are served. Finally, the
"exceptional
products"
gives credence
Congress's
"exceptional products" interpretation
interpretation gives
credence to Congress's
191. Sykes,
191.
Sykes, 484 F. Supp. 2d at 297.
221, at *23.
192. Wright, 2008 Phila. Ct. Com. Pl.
PI. LEXIS
LEXIS 221,
*23.
193. In Ferrari,
specifically noted that the Vaccine
Ferrari, the Georgia Supreme
Supreme Court specifically
Vaccine Act does not
not
193.
necessarily protect manufacturers
manufacturers from design defect
defect suits, but rather protects
protects them from liability
liability for
unavoidable
unavoidable side effects. Am. Home Prods. Corp. v. Ferrari, 668 S.E.2d 236, 242 (Ga. 2008).
194.
scientific evidence strongly
strongly
194. Additionally, the Vaccine Act could
could be revised to list side effects
effects that scientific
vaccination, such as autism, and stipulate that vaccine manufacturers
manufacturers are
suggests are not the result of vaccination,
not subject to design defect
defect claims for these particular side effects, as well.
195. Bruesewitz v. Wyeth,
Wyeth, Inc., 508 F. Supp. 2d 430, 440 (E.D. Pa. 2007)
2007) ("[T]he
("[T]he policy of the
195.
manufacturers from the potential
Vaccine Act is to protect
protect the national vaccine supply by protecting
protecting manufacturers
inconsistencies of the 50-state
.... ").
50-state tort system ....
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ultimate goals in enacting the Act: protection
protection of America's supply of
of
ultimate
number of
compensation for the small
childhood vaccines and compensation
of
96
immunization.'
by
harmed
children who are invariably
invariably
by immunization. 196
CONCLUSION
CONCLUSION

The National Childhood
Childhood Vaccine
enacted
Vaccine Injury Act of 1986 was enacted
to protect the interests of both the American
American public, by preserving the
supply of necessary and critical childhood vaccines,
vaccines, and of vaccineinjured individuals, by ensuing they receive
compensation
receive adequate
adequate compensation
197
97
for their suffering.'
suffering.
Congress determined that the best method of
of
achieving both these crucial goals was to limit potential plaintiffs'
plaintiffs'
remedies in tort claims based
on
state
law
causes
of
action
when
their
based
198
defect.
design
on an
theory of recovery
recovery is based on
an alleged
alleged design defect. 198
Unfortunately, the scope of the preemptive language
language of the Vaccine
Act, found in §§ 300aa-22(b),
300aa-22(b), is ambiguous
ambiguous and subject to two
1 99
differing
interpretations occur
differing interpretations. 199 These differing interpretations
because
§
300aa-22(b)
is
modeled
after
comment
because 300aa-22(b)
comment k to section 402A
of the Restatement
Restatement (Second) of Torts, which itself has been the
" As a result, several courts
subject of disagreement
disagreement among courts. 2200
have concluded § 300aa-22(b)
300aa-22(b) of the Vaccine
Vaccine Act imposes a total bar
2011
on design defect claims arising from vaccine-related
vaccine-related injuries. 20
In
American Home Products
Products Corp.
Corp. v. Ferrari,
Ferrari,however, the Georgia
Georgia
American
defect
Supreme Court decided that the Vaccine
Vaccine Act only bars design defect
case-by-case basis,
claims if the2 injuries are deemed, on a case-by-case
0
2202
unavoidable.
conflict
The Georgia
Georgia Supreme
Supreme Court's decision has led to interstate conflict
as to whether
whether the Vaccine
Vaccine Act provides an absolute bar to design
defect claims under state law, and resulted in inconsistent application
application

196.
196.
197.
198.
198.
199.
200.
201.I.
20
202.

(1986),
H.R. REP.
REp. No.
No. 99-908,
99-908, at 5 (I
986), as reprinted in 1986 U.S.C.C.A.N.
V.S.C.C.A.N. 6344, 6348.
See discussion supra Part
I.A.1;
Part LA.
I ; supra
supra note 36.
supraPart
See discussion supra
Part I.A.1.
I.A.I.
See discussion supra
supraPart
I.A.2.
Part LA.2.
ll.B. 1.
See discussion supra Part
Part n.B.I.
See discussion supra Part LA.2;
I.A.2; supra note 80 and accompanying
accompanying text.
I.A.3; discussion
.c; discussion supra Part H.B.2.
See discussion supra Part LA.3;
discussion supra Part
Part ll.B.
II.8.l.c;
n.8.2.
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°3
level.2203
Ferrari
of the Vaccine Act on a nationwide leve1.
Furthermore, Ferrari
will likely lead to an increase in vaccine design defect litigation,
°4
increasing
increasing the costs of vaccine production for manufacturers.2204
manufacturers to leave
Escalating litigation costs may also lead some manufacturers
manufacturing market altogether, further threatening
the vaccine manufacturing
threatening the
20 5 The
nation's already fragile supply of childhood vaccines. 2os
Vaccine
Act sought to prevent just such a scenario by shielding manufacturers
litigation-namely design defect claims-while
from certain types of litigation-namely
compensation for vaccine-injured
also ensuring
adequate and timely compensation
20 6
individuals. 206
The two goals of the Vaccine Act can be properly
properly effected
effected by
applying an application
300aa-22(b) that classifies
classifies
application of comment
comment k to § 300aa-22(b)
20 7 By
vaccines as special
special products of exceptional social importance.
importance?07
By
granting routine childhood vaccines
products" status,
vaccines an "exceptional
"exceptional products"
Supreme Court can ensure the "unavoidably
"unavoidably unsafe"
unsafe" exception
exception
the Supreme
applies to these vaccines
vaccines and shield them from design defect suits by
208
208
statute.
Although
Although it is unclear
unclear from the legislative history
underlying the Vaccine Act which interpretation
interpretation of comment k
20 9 it is
Congress
Congress intended to adopt when enacting
enacting § 300aa-22(b),
300aa-22(b)/09
quite clear that Congress
childhood
Congress sought to protect the supply of childhood
vaccines
by insulating
insulating vaccine
vaccine
vaccines available to the American
American public
public by
21
0 An interpretation
manufacturers
from
certain
forms
of
tort
liability.
manufacturers
liability.210
interpretation
of comment
comment k, and thus § 300aa-22(b),
300aa-22(b), that recognizes
recognizes the
importance
"exceptional
vaccines by classifying
classifying them as "exceptional
importance of childhood vaccines
products" serves
compensation
products"
serves Congress's intent, while still ensuring compensation
for vaccine-injured
children.
vaccine-injured children.
In
In the meantime,
meantime, Stefan Ferrari
Ferrari and his family may soon
soon be
be able
able to
pursue
pursue their claims
claims against
against the
the vaccine
vaccine manufacturers
manufacturers at the trial
203. See
168See discussion
discussion supra
supra Part HLI.A;
ITl.A; supra notes 160-161
160-161 and
and accompanying
accompanying text;
text; supra
supra notes
notes 168-

accompanying text.
170 and
and accompanying

204. See discussion
discussion supra
supra Part
Part llI.A;
ITl.A; supra
supra note 164 and accompanying
accompanying text.
205.
1ll.A; supra
20S. See discussion
discussion supra
supra Part
Part ITl.A;
supra notes
notes 160-163
160-163 and
and accompanying
accompanying text.
206. See
1.
See discussion
discussion supra
supra Part
Part I.A.
LA. 1.
207. See
See discussion
discussion supra
supra Part
Part 11I.B.
llI.B.
208. See discussion
discussion supra
supra Part
Part IlI.C.
llI.C.
209. See
1; supra
accompanying text.
See discussion
discussion supra
supra Part
Part H.B.
IT.B.l;
supra note 146 and accompanying
210. See
See discussion
discussion supra
supra Part
Part I.A.1;
LA.l; see also
also H.R.
H.R. REp.
REp. No.
No. 99-908,
99-908, atat 26
26 (1986),
(1986), as
as reprinted
reprinted in
1986
1986 U.S.C.C.A.N.
U.S.C.C.A.N. 6344,
6344, 6367.
6367.
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2111
courts. 21
They may have to wait a bit
court level in the Georgia
Georgia courtS.
bit
Court's
longer, however-shortly
however-shortly after the Georgia Supreme Court's
manufacturers filed a petition for certiorari In
decision, the vaccine
vaccine manufacturers
in
212
212
Court.
Supreme
States
the United
Supreme COurt.

211. See McDonald, supra
211.
supra note 19,
19, at 1.
J.
212. Petition for Writ of Certiorari,
Certiorari, Am. Home
Home Prods. Corp. v. Ferrari,
Ferrari, 129 S.
S. Ct. 2786 (Mar. 5,
5, 2009)
2009)
(No. 08-1120). Shortly thereafter,
Bruesewitz
thereafter, on March 27,
27, 2009, the Third Circuit issued
issued its opinion
opinion in Bruesewitz
v. Wyeth.
Wyeth, Inc.
Inc. 561 F.3d 233 (3d Cir. 2009). In that decision, the Third Circuit affirmed the district
court's holding
vaccine
holding that 42 U.S.C.
U.S.C. § 300aa-22(b)
300aa-22(b) expressly preempts design defect
defect claims against vaccine
manufacturers.
Ferrari,the United
manufacturers. Id.
Id. at 428. Following briefing
briefmg by the parties and amici curiae
curiae in Ferrari,
States Supreme Court invited the Solicitor General to file a brief expressing
expressing the views of the United
States. Am. Home Prods. Corp. v. Ferrari, 129 S.
(2009) (No. 08-1120). However, before
S. Ct. 2786 (2009)
before the
Solicitor
supplemental brief with the Court, notifying it that
Solicitor General
General filed her brief, the Ferraris
Ferraris filed a supplemental
they had voluntarily dismissed
dismissed the design
design defect claims against the petitioners
petitioners without prejudice.
prejudice.
Supplemental
for Respondents
1, Am. Home
Supplemental Brief
Brieffor
Respondents at I,
Home Prods. Corp. v. Ferrari,
Ferrari, 129 S. Ct. 2786 (Oct. 7,
2009)
2009) (No. 08-1120). Thus, the Ferraris
Ferraris argued, the case
case was moot and the petition
petition for certiorari
certiorari should
should
be dismissed.
Id. at 2. The petitioners quickly
quickly filed their own supplemental brief in response, urging the
dismissed. Id.
Court to grant the writ of certiorari,
alternative, hold the case pending resolution of Bruesewitz
Bruesewitz
certiorari, or, in the alternative,
(which,
certiorari pending
(which, by this time, also had a petition
petition for certiorari
pending with the U.S. Supreme Court).
Supplemental
Supplemental Brief for Petitioners at 6, Am. Home Prods. Corp. v. Ferrari, 129 S. Ct. 2786 (Oct. 20,
2009)
2009) (No. 08-1120). The petitioners argued the Ferraris'
Ferraris' voluntary
voluntary dismissal
dismissal without prejudice did not
not
render the case moot, because
because Georgia law allows the Ferraris
Ferraris to refile their claims at any time for at
least
Supreme Court had not been
least nine more years. Id.
Id. at 2. Furthermore,
Furthermore, the judgment of the Georgia Supreme
vacated, and therefore stands as binding precedent
precedent in Georgia. Id.
Id. at 1.
J. Finally, on January 29, 2010, the
Solicitor
Solicitor General
General filed her brief on behalf
behalf of the United States. Brief for the United States
States as Amicus
Curiae, Am. Home Prods. Corp. v. Ferrari, 129
brief
129 S. Ct. 2786 (Jan. 29, 2010)
2010) (No. 08-1120). The brief
urged
Supreme Court to grant the petition
urged the
the Supreme
petition for a writ of certiorari
certiorari in Bruesewitz,
Bruesewitz, and to hold the
petition
certiorari in Ferrari
Ferraripending the disposition of Bruesewitz,
Bruesewitz, or, in the alternative,
petition for a writ of certiorari
alternative, to
dismiss the Ferrari
Ferrari petition (because of the potential mootness question). Id.
Id. at I. The Solicitor General
General
stated the "Supreme Court of Georgia erred,"
erred," and that the court's Ferrari
Ferrariopinion "frustrates
stated
"frustrates Congress's
Congress's
intent to stabilize the market
Because the issue
market for vaccines critical to children's
children's health."
health." Id.
Id at 7. Because
presented
and Bruesewitz is "pressing,"
Ferrari and
"pressing," the Solicitor General urged
urged the Court
Court to review
review the
presented in Ferrari
question presented. Id.
ramifications from the Georgia Supreme
Id. Thus, serious
serious ramifications
Supreme Court's
Court's Ferrari
Ferrari opinion
opinion
are
certiorari in Bruesewitz
Bruesewitz or Ferrari.
Ferrari.
are quite likely, unless the Supreme Court intervenes by granting certiorari
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